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Abstract:
Objectives: Persistently impaired culprit artery flow (<TIMI 3) during 
primary percutaneous coronary intervention is a surrogate for failed 
myocardial perfusion. We evaluated the effects of intracoronary alteplase 
according to TIMI flow grade immediately preceding drug administration. 
Methods: In T-TIME, patients ≤6 hours from onset of ST-elevation 
myocardial infarction (STEMI), were randomised to placebo, alteplase 
10mg, or alteplase 20mg, administered by infusion into the culprit 
artery, pre-stenting. In this pre-specified, secondary analysis, coronary 
flow was assessed angiographically, at the point immediately before drug 
administration. Microvascular obstruction, myocardial haemorrhage and 
infarct size were assessed by cardiovascular magnetic resonance (CMR), 
at 2-7 days and 3 months. 
Results: TIMI flow was assessed after first treatment (balloon 
angioplasty/ aspiration thrombectomy), immediately pre-drug 
administration, in 421 participants (mean age 61±10 years, 85% male), 
and was 3, 2, or 1 in 267, 134, and 19 participants respectively. In 
patients with TIMI flow≤2 pre-drug there was higher incidence of 
microvascular obstruction with alteplase (alteplase 20mg [53.1%] and 
10mg [59.5%] combined vs. placebo [34.1%]; OR=2.47 [95% CI: 1.16-
5.22, p=0.018] interaction p=0.005) and higher incidence of myocardial 
haemorrhage (alteplase 20mg [53.1%] and 10mg [57.9%] combined vs. 
placebo [27.5%]; OR=3.26 [95% CI: 1.44-7.36, p=0.004] interaction 
p=0.001). These effects were not observed in participants with TIMI 3 
flow pre-drug. There were no interactions between TIMI flow pre-drug, 
alteplase and 3-month CMR findings. 
Conclusion: In patients with impaired culprit artery flow (<TIMI 3) after 
initial balloon angioplasty/ thrombus aspiration, intracoronary alteplase 
was associated with increased presence of microvascular obstruction and 
myocardial haemorrhage.   
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67 Abstract
68 Objectives: Persistently impaired culprit artery flow (<TIMI 3) during primary percutaneous 
69 coronary intervention is a surrogate for failed myocardial perfusion. We evaluated the effects 
70 of intracoronary alteplase according to TIMI flow grade immediately preceding drug 
71 administrati n.
72 Methods: In T-TIME, patients ≤6 hours from onset of ST-elevation myocardial infarction 
73 (STEMI), were randomised to placebo, alteplase 10mg, or alteplase 20mg, administered by 
74 infusion into the culprit artery, pre-stenting. In this pre-specified, secondary analysis, 
75 coronary flow was assessed angiographically, at the point immediately before drug 
76 administration. Microvascular obstruction, myocardial haemorrhage and infarct size were 
77 assessed by cardiovascular magnetic resonance (CMR), at 2-7 days and 3 months.
78 Results: TIMI flow was assessed after first treatment (balloon angioplasty/ aspiration 
79 thrombectomy), immediately pre-drug administration, in 421 participants (mean age 61±10 
80 years, 85% male), and was 3, 2, or 1 in 267, 134, and 19 participants respectively. In patients 
81 with TIMI flow ≤2 pre-drug there was higher incidence of microvascular obstruction with 
82 alteplase (alteplase 20mg [53.1%] and 10mg [59.5%] combined vs. placebo [34.1%]; 
83 OR=2.47 [95% CI: 1.16-5.22, p=0.018] interaction p=0.005) and higher incidence of 
84 myocardial haemorrhage (alteplase 20mg [53.1%] and 10mg [57.9%] combined vs. placebo 
85 [27.5%]; OR=3.26 [95% CI: 1.44-7.36, p=0.004] interaction p=0.001). These effects were 
86 not observed in participants with TIMI 3 flow pre-drug. There were no interactions between 
87 TIMI flow pre-drug, alteplase and 3-month CMR findings. 
88 Conclusion: In patients with impaired culprit artery flow (<TIMI 3) after initial balloon 
89 angioplasty/ thrombus aspiration, intracoronary alteplase was associated with increased 
90 presence of microvascular obstruction and myocardial haemorrhage.  
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91 Key Questions
92 What is already known?
93  Microvascular obstruction following ST-segment elevation myocardial infarction 
94 (STEMI) confers a worse prognosis. 
95  There are no evidence-based treatments for microvascular obstruction.
96 What does this study add?
97  Adjunctive intracoronary alteplase, during primary percutaneous coronary 
98 intervention (PCI), was associated with increased presence of microvascular 
99 obstruction and myocardial haemorrhage, in participants with impaired culprit artery 
100 flow (TIMI <3) at the time of study drug administration.
101  Low-dose intracoronary lytic therapy in patients with STEMI, who have impaired 
102 coronary flow may be harmful.
103 How might this impact on clinical practice?
104  The findings are relevant to trials of adjunctive intracoronary fibrinolytic therapy 
105 during primary PCI, and as a disincentive to clinicians when considering bail-out lytic 
106 therapy for angiographic “no reflow”.
107  Future studies evaluating the effects of intracoronary lytic therapy should limit 
108 recruitment to patients with TIMI 3 flow at the time of study drug administration, 
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115 ST-segment elevation myocardial infarction
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CMR Cardiovascular magnetic resonance
eGFR Estimated glomerular filtration rate
IQR Interquartile range






PCI Percutaneous coronary intervention
QCA Quantitative coronary angiography
SD Standard deviation
STEMI ST-segment elevation myocardial infarction
TIMI Thrombolysis in Myocardial Infarction
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136 Introduction
137 Despite routinely restoring epicardial coronary patency with primary percutaneous 
138 coronary intervention (PCI), microvascular obstruction (MVO) affects about half of 
139 patients(1) and confers an adverse prognosis(2, 3). A key component of MVO is distal 
140 embolization and microvascular thrombi(4-6). 
141 In the T-TIME trial (NCT02257294), we hypothesised that low-dose intracoronary 
142 alteplase, administered shortly after balloon angioplasty or aspiration thrombectomy, before 
143 stenting, would reduce intracoronary and microvascular thrombosis, and distal embolization, 
144 thereby reducing MVO. However, as assessed by contrast-enhanced cardiovascular magnetic 
145 resonance (CMR), MVO did not differ with intracoronary alteplase vs. placebo(7). 
146 Interestingly, in a T-TIME subgroup analysis, participants presenting 4 hours after symptom 
147 onset, had a dose dependent increase in mean amount of MVO and myocardial haemorrhage 
148 with alteplase vs. placebo(8). Invasively measured index of microcirculatory resistance did 
149 not differ with intracoronary alteplase vs. placebo(9), and there was no difference in clinical 
150 outcomes at 1-year between treatment groups(10).
151 Coronary angiography allows a semi-quantitative grading of coronary flow, according 
152 to the Thrombolysis in Myocardial Infarction (TIMI) flow grades(11). Persistently reduced 
153 flow in the culprit coronary artery (TIMI flow <3) after first treatment, is termed “no-
154 reflow”(12, 13). TIMI flow <3 is a surrogate for impaired myocardial perfusion(14, 15) and 
155 predicts heart failure(16), larger infarct size(14) and mortality(16, 17).  TIMI flow <3 early 
156 during the primary PCI procedure (pre-stenting) may be even more closely associated with 
157 mortality(18, 19) and larger infarct size(19), than TIMI flow <3 post-stenting. In contrast, 
158 recovery of TIMI 3 flow in the culprit artery after first treatment (balloon angioplasty/ 
159 thrombus aspiration) may help restore microvascular function(15).
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160 Persisting impairment of antegrade flow in the culprit artery may influence the effect 
161 of intracoronary alteplase. We hypothesised that impaired coronary flow reduces the effective 
162 delivery of alteplase to the microcirculation. The primary aim of this pre-specified secondary 
163 analysis was to assess the associations between TIMI flow grade, treatment group (placebo, 
164 alteplase 10mg, alteplase 20mg), and MVO.  We also investigated associations between TIMI 
165 flow grade, treatment group and the secondary endpoints from the T-TIME trial(10).
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166 Methods
167 Trial Design
168 T-TIME was a randomised, double-blind, parallel group, phase 2 clinical trial of low-
169 dose adjunctive intracoronary alteplase during primary PCI(7, 10). Patients were enrolled by 
170 11 U.K. hospitals, from March 2016 to December 2017. The methodology has been described 
171 previously in detail(7) (Figure 1).
172 Consent 
173 Screening and study drug administration occurred during standard care primary PCI. 
174 Witnessed verbal assent to participate was obtained in the catheterisation laboratory. Written 
175 informed consent was subsequently obtained on the ward. The study was approved by the 
176 West of Scotland Research Ethics Committee (reference 13-WS-0119). 
177 Eligibility
178 Patients were eligible to participate if they presented with persistent ST-segment 
179 elevation or recent left bundle branch block, ≤6 hours from symptom onset, and with an 
180 occluded culprit artery (TIMI 0 flow), TIMI 1 flow (contrast passes beyond the obstruction, 
181 but fails to opacify the entire distal coronary bed), or reduced coronary flow (TIMI 2 flow, 
182 slow but complete filling), in the presence of TIMI thrombus grade ≥2.
183 Key exclusion criteria (Supplemental Methods) included a functional coronary 
184 collateral supply (Rentrop grade ≥2) to the culprit artery and cardiogenic shock.
185 Randomisation and Blinding
186 Participants were randomised using an interactive voice response-based system. The 
187 randomisation sequence was computer generated, using the method of randomised permuted 
188 blocks of length 6, with stratification by location of MI (anterior vs. non-anterior). The 
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189 allocation sequence was on a 1:1:1 basis, between placebo and the reduced dose of alteplase 
190 groups (10mg and 20mg), i.e. one tenth, or one fifth, of standard dose. The participants, staff 
191 and researchers were blinded to the treatment group allocation.
192 Interventions
193 The trial protocol encouraged achieving TIMI flow grade ≥2, using balloon 
194 angioplasty/ aspiration thrombectomy, prior to randomisation. After randomisation, the 
195 allocated intervention was prepared, during which TIMI flow grade deteriorated in a minority 
196 of patients prior to study drug administration, before stent deployment. The 20ml volume of 
197 study drug was manually infused into the culprit artery, over 5-10 minutes, proximal to the 
198 culprit lesion, using either an intracoronary catheter, or the guiding catheter if selectively 
199 engaged.
200 CMR
201 CMR (1.5 Tesla) was analysed by an investigator who was blind to the angiographic 
202 findings and treatment allocation. A second read was undertaken by a cardiologist with level 
203 3 CMR certification. MVO presence and extent (% left ventricular [LV] mass) was revealed 
204 by late gadolinium enhancement (LGE), 10-15 minutes after administration of gadolinium-
205 based contrast media. MVO was defined as a dark zone on early gadolinium enhanced 
206 imaging 1, 3, 5 and 7 minutes post-contrast injection that persisted within an area of LGE at 
207 15 minutes. The myocardial mass of the dark zone was quantified by manual delineation and 
208 expressed as % of LV mass. 
209 Myocardial haemorrhage presence and extent (% LV mass) was revealed by T2* 
210 mapping. A region of reduced signal intensity within the infarcted area, with a T2* value 
211 <20ms was considered to confirm the presence of myocardial haemorrhage. This area was 
212 manually delineated and expressed as % LV mass. 































































Confidential: For Review Only
CONFIDENTIAL – EMBARGO APPLIES 12
213 The presence of acute infarction was established based on abnormalities in cine wall 
214 motion, rest first-pass myocardial perfusion, and LGE imaging, in 2 imaging planes. The 
215 myocardial mass of late gadolinium was quantified using a 5-standard deviation (SD) semi-
216 automated method and expressed as % of total LV mass. Myocardial salvage was calculated 
217 by subtraction of percent infarct size from percent area-at-risk (as reflected by the extent of 
218 oedema) and the myocardial salvage index was calculated by dividing the myocardial salvage 
219 area by the initial area-at-risk. 
220 MVO and myocardial haemorrhage were reported on CMR scans acquired 2–7 days 
221 post-STEMI. The other CMR parameters were reported from the 2–7 day and 3-month scans 
222 (Supplement). 
223 Angiography, ECGs and Troponin
224 The ECG and angiographic parameters were determined by blinded core laboratory 
225 analysis (blinded to CMR data and treatment allocation).
226 The angiograms were analysed prospectively by one researcher, and then a second 
227 read was undertaken by an experienced interventional cardiologist. Discrepancies were 
228 resolved by consensus agreement. The following were assessed in the culprit artery: TIMI 
229 flow grade, TIMI frame count, myocardial perfusion grade, TIMI thrombus grade, and plaque 
230 characteristics (Supplement).
231 The angiogram acquisition protocol required stored fluoroscopy of study drug 
232 administration, to enable verification by the core laboratory that the guide catheter was 
233 selectively engaged in the culprit artery during drug delivery. This also enabled core 
234 laboratory evaluation of TIMI flow grade immediately before study drug administration, 
235 which was submitted to the data coordination centre prior to database lock. Participants were 
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236 grouped according to TIMI flow grade (2 vs. 3) in the culprit artery immediately preceding 
237 study drug administration.
238 The absolute percentage ST-segment resolution on ECGs obtained 60 minutes after 
239 reperfusion (i.e. after initial restoration of flow in the culprit artery), compared to pre-
240 reperfusion was calculated. Troponin T area-under-the-curve (AUC) was measured in blood 
241 samples obtained immediately pre-reperfusion (0 hours), then at 2- and 24-hours post-
242 reperfusion. 
243 Coagulation
244 Coagulation and haemostasis parameters were measured in peripheral blood samples 
245 taken pre-reperfusion, then 2, and 24 hours post-reperfusion. The parameters included 
246 fibrinogen and plasminogen (both measures of systemic fibrinolysis), fibrin D-dimer (a 
247 measure of fibrin lysis), tissue plasminogen activator (a measure of endogenous fibrinolytic 
248 system activation and circulating alteplase) and prothrombin fragment F1+2 (a measure of 
249 thrombin generation). 
250 Statistical Analysis
251 This study was a pre-specified secondary analysis in the T-TIME trial population. The 
252 analyses were performed according to treatment received (alteplase 20mg, 10mg, or placebo). 
253 The trial endpoints were assessed using linear regression (continuous variables), or logistic 
254 regression (binary variables), to make treatment effect estimates. In regression models, 
255 logarithmic, or square root transformations were used where necessary to improve model 
256 residual distributions. As MVO extent was not normally distributed, we adopted square root 
257 transformation for MVO extent, in keeping with the analysis plan for the main T-TIME 
258 trial(7). However, as 56% of patients had zero values for MVO extent we also performed a 
259 sensitivity analysis using bootstrapping confidence intervals (CIs) to model this endpoint. 
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260 Regression models were used to assess treatment effects through interactions, with treatment 
261 as 3-level and 2-level categorical variables. The regression analyses were adjusted for the 
262 location of MI (anterior vs. non-anterior). All tests were 2-tailed and assessed at the 5% 
263 significance level. There was no imputation for missing values and there were no adjustments 
264 for multiple statistical comparisons. Given the high proportion of participants with a 0 value 
265 for MVO extent and myocardial haemorrhage extent, the median values for MVO and 
266 myocardial haemorrhage were 0 for all groups, therefore the mean (SD) values were reported, 
267 despite not being ideal summaries for these data. Data were analysed using R (version 3.6.1, 
268 R Development Core Team, Auckland, New Zealand) and SPSS (version 25.0, SPSS, IBM, 
269 Armonk, NY, USA).
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270 Results
271 Population
272 Four hundred and forty participants were randomised to placebo, alteplase 10mg, or 
273 alteplase 20mg. Nineteen patients were excluded from the analysis (Figure 2): in 7 patients 
274 TIMI flow grade was unevaluable immediately before study drug administration; in 5 
275 participants study drug was not given; in 3 participants study drug was administered post-
276 stent implantation, an ; in 4 participants study drug was administered distal to the lesion.
277 The analysis therefore included 421 participants (mean age 61±10 years, 85% male). 
278 Out of the 421 participants who were included, 1 participant who was randomised to 10mg of 
279 alteplase received 20mg, and 1 participant randomised to placebo received 20mg of alteplase, 
280 because of handling errors. 
281 The baseline and procedural characteristics for participants with TIMI flow ≤2 
282 (n=154) or TIMI 3 flow (n=267) pre-study drug were broadly similar (Tables 1, 2 and 
283 Supplemental Table 1). 
284 The distribution of TIMI flow grades immediately before study drug administration 
285 was as follows: TIMI grade 0 in 1 participant (0.2%), who received alteplase 10mg; TIMI 
286 grade 1 in 19 participants (4.5%), of whom 8 received placebo, 4 received alteplase 10mg, 
287 and 7 received alteplase 20mg; TIMI grade 2 in 134 participants (31.8%), of whom 42 
288 received placebo, 44 received alteplase 10mg and 48 received alteplase 20mg, and; TIMI 
289 grade 3 in 267 participants (63.4%), of whom 92 received placebo, 88 received alteplase 
290 10mg and 87 received alteplase 20mg. 
291 In multivariable logistic regression analysis, only anterior MI was associated with 
292 TIMI flow ≤2 pre-study drug (odds ratio [OR] 1.61 [95% CI 1.07-2.43] p=0.023). Ischaemic 
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293 time (symptom onset to reperfusion time) was not associated with TIMI flow 2 immediately 
294 pre-study drug (OR 1.05 [95% CI 0.91-1.22] p=0.499).
295 CMR Parameters
296 CMR was performed in 387 participants (92%) at 2–7 days (Table 3 and 
297 Supplemental Table 2), and in 358 participants (85%) at 3-months post-STEMI (Table 4 and 
298 Supplemental Table 2). The CMR results (2-7 day) stratified by location of MI are shown in 
299 Supplemental Table 3. Baseline/ procedure characteristics were similar for patients who had 
300 MVO data available (n=383) vs. those with missing MVO data (n=38) (Supplemental Tables 
301 4 and 5). This suggests that data was missing at random, and the impact of missing data 
302 should be affecting each treatment group in a similar way. 
303 Mean MVO extent was higher in patients who had TIMI flow 2 (3.7  6.0%) vs. 
304 TIMI 3 flow (2.3  4.2%) immediately pre-drug (coefficient: 0.33 [95% CI: 0.05-0.60] 
305 p=0.022 [derived from linear regression, using square root transformed MVO]). 
306 In participants with TIMI 3 flow pre-study drug, there were no associations between 
307 alteplase and infarct characteristics, apart from an increase in LV end-diastolic volume with 
308 alteplase 10mg vs. placebo (Tables 3 and 4, and Supplemental Table 2). 
309 MVO
310 Participants with TIMI flow ≤2 pre-study drug, had MVO present more often with 
311 alteplase (placebo, 34.1% [n=15/44]; alteplase 10mg, 59.5% [n=25/42]; alteplase 20mg, 
312 53.1% [n=26/49]; OR for alteplase 10mg and 20mg combined vs. placebo 2.47 [95% CI: 
313 1.16-5.22] p=0.018) (Table 3 and Figure 3A). Interactions were observed for association with 
314 MVO presence, between TIMI flow pre-drug, and treatment analysed as 3-, or 2-level 
315 categorical variables (p=0.013 and p=0.005 respectively) (Table 3). When the 19 patients 
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316 with TIMI 1 flow and the one patient with TIMI 0 flow immediately pre-drug were excluded, 
317 significant interactions remained between alteplase, TIMI flow pre-drug (2 vs. 3) and the 
318 presence of MVO (p=0.022) (Supplemental Table 6).
319 Participants with TIMI flow ≤2 pre-drug, had increased extent of MVO (% LV mass) 
320 with alteplase (placebo 2.6 ± 5.7%, alteplase 10mg 2.7 ± 3.9%, alteplase 20mg 5.4 ± 7.4%, 
321 estimated mean difference [for MVO analysed on a square root scale] alteplase 20mg and 
322 10mg combined vs. placebo 0.53 [95% CI: 0.06-1.00] p=0.027) (Table 3). There was an 
323 interaction between MVO extent (% LV mass), TIMI flow pre-drug and treatment, when 
324 alteplase 10mg and 20mg were combined vs. placebo (p=0.041), but not for treatment as a 3-
325 level categorical variable (p=0.070) (Table 3). On bootstrap linear regression analysis, 20mg 
326 alteplase was associated with MVO extent when compared to placebo in patients with TIMI 
327 flow 2 pre-drug (mean difference: 3.37 [95% CI: 0.77-6.89] p=0.016), but not in patients 
328 with TIMI 3 flow pre-drug (mean difference: 1.91 [95% CI: -0.74, 3.01] p=0.287) 
329 (Supplemental Table 7).
330 Myocardial Haemorrhage
331 Myocardial haemorrhage presence/ absence was evaluable in 366 participants at 2-7 
332 days, and myocardial haemorrhage extent was evaluable in 348 participants.
333 In participants with TIMI flow ≤2 pre-study drug, myocardial haemorrhage occurred 
334 more often with alteplase than placebo (alteplase 20mg, 53.1% [26/49], alteplase 10mg, 
335 57.9% [n=22/38] vs. placebo, 27.5% [n=11/40]; OR for alteplase 10mg and 20mg combined 
336 vs. placebo: 3.26 [95% CI: 1.44-7.36] p=0.004) (Figure 3A). Interactions were observed 
337 between myocardial haemorrhage presence, TIMI flow pre-drug and treatment, analysed as 
338 3-level, or 2-level categorical variables (p=0.004 and p=0.001 respectively) (Table 3). When 
339 the 19 patients with TIMI 1 flow and the one patient with TIMI 0 flow immediately pre-drug 
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340 were excluded, significant interactions remained between alteplase, TIMI flow pre-drug (2 
341 vs. 3) and the presence of myocardial haemorrhage (p=0.009) (Supplemental Table 6). 
342 Infarct Size, Myocardial Salvage Index, LV Ejection Fraction and LV Volumes at 2-7 days 
343 and 3-months
344 An interaction was observed for association with infarct size (2-7 day), between TIMI 
345 flow and treatment analysed as a 2-level categorical variable (p=0.026). Similar findings 
346 were observed for myocardial salvage index at 2–7 days post-STEMI (Table 3).
347 In participants with TIMI flow ≤2 pre-study drug, alteplase was not associated with 
348 LV ejection fraction, or LV volumes 2-7 days post-STEMI (Table 3, Supplemental Table 2), 
349 or at 3-months (Table 4, Supplemental Table 2).
350 Angiographic and ECG Parameters
351 The inter-observer reliability for TIMI flow grade pre-study drug, assessed in 65 
352 consecutive participants, was excellent (kappa=0.94). Occlusion of the culprit coronary artery 
353 after study drug administration occurred in 44 out of 334 patients (13%). There were no 
354 interactions between TIMI flow pre-drug, alteplase and angiographic or ECG surrogates of 
355 failed microvascular reperfusion (Supplemental Table 8).  
356 Blood Chemistry
357 There were no interactions between TIMI flow pre-drug, alteplase and troponin T 
358 measured in 306 participants (Supplemental Table 8). 
359 Coagulation
360 Regarding coagulation data (Table 5, Supplemental Table 9), there was an increase in 
361 fibrin D-dimers (a product of fibrin lysis), and decrease in plasminogen and fibrinogen, 2 
362 hours post-primary PCI relative to baseline, with alteplase vs. placebo, regardless of TIMI 
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363 flow grade pre-drug. This is consistent with what is expected following intra-arterial 
364 fibrinolysis. There was an increase in prothrombin fragment F1+2 (a measure of thrombin 
365 activation) two hours post-primary PCI relative to baseline, with alteplase vs. placebo, 
366 regardless of TIMI flow grade pre-drug (Table 5).
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367 Discussion 
368 Low-dose adjunctive intracoronary alteplase administered early during primary PCI, 
369 was associated with increased MVO and myocardial haemorrhage in participants who had 
370 TIMI flow ≤2 pre-drug administration (Figure 3A). These effects were not observed in 
371 participants with normalised TIMI 3 flow. 
372 Our findings contrast with a previous study (n=95), which reported smaller infarct 
373 size at 6 months in patients given intracoronary streptokinase immediately post-primary 
374 PCI(20). Differences between the previous study(20) and ours include the previous study was 
375 not double-blinded, streptokinase is not fibrin specific, whereas alteplase is, and streptokinase 
376 was delivered post-stent insertion in the previous study (when 89% of the cohort had TIMI 3 
377 flow), whereas we administered alteplase pre-stent implantation. 
378 We might speculate that impaired antegrade coronary flow would in turn lead to 
379 inadequate drug delivery to the microcirculation, resulting in less effective microvascular 
380 reperfusion. In fact, increased fibrin D-dimer and lower plasminogen concentrations were 
381 observed with alteplase in patients with TIMI flow ≤2 pre-drug (Table 5, and Supplemental 
382 Table 9), which indicates that fibrinolysis did indeed occur in this group of participants. 
383 Our findings may be related to the undesired procoagulant effects of fibrinolytic 
384 therapy (Figure 3B). In circumstances of slow microvascular flow, intracoronary alteplase 
385 potentially promotes the procoagulant effects of alteplase(21), thereby promoting 
386 microvascular thrombosis and worsening MVO. Indeed, increased prothrombin fragment F1+2 
387 concentrations were observed with intracoronary alteplase (Table 5), despite therapeutic 
388 anticoagulation with heparin, indicating thrombin generation and increased risk of 
389 thrombosis(22). 
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390 Our findings may suggest that in circumstances of reduced antegrade flow, 
391 myocardial perfusion is reduced leading to prolonged, higher local concentrations of 
392 alteplase, due to reduced washout of alteplase from the microcirculation. TIMI 3 flow is not 
393 synonymous with normal myocardial perfusion, for example in our population 42% of 
394 patients with TIMI 3 flow pre-study drug administration had MVO present. However, 
395 participants with TIMI flow ≤2 immediately pre-study drug had more extensive 
396 microvascular injury, evidenced by these patients having significantly more MVO than the 
397 patients with TIMI 3 flow pre-drug. Myocardium with extensive microvascular damage from 
398 coronary occlusion, is characterised by loss of capillary integrity. In these circumstances, 
399 intracoronary fibrinolysis appears to worsen extravasation of erythrocytes, resulting in 
400 myocardial haemorrhage in the infarct core (an irreversible manifestation of persistent 
401 MVO). An increase in extravasation of blood into the interstitial space of the infarct core 
402 results in external compression of capillaries, which worsens MVO (Figure 3B). 
403 Insights from previous studies of glycoprotein IIbIIIa inhibitors, are consistent with 
404 our findings(23, 24). An animal study demonstrated an increased incidence of myocardial 
405 haemorrhage with the addition of intracoronary glycoprotein IIbIIIa inhibitors(24), and in 
406 humans peri-procedural glycoprotein IIbIIIa inhibitors have also been associated with 
407 myocardial haemorrhage(24). 
408 Our findings are relevant to clinicians when considering bail-out lytic therapy in acute 
409 STEMI patients with massive thrombus and angiographic “no reflow”. Our findings are also 
410 relevant to ongoing clinical trials. Notably, the RESTORE-MI trial (NCT03998319) is 
411 randomising patients with STEMI (n=800) to adjunctive intracoronary tenecteplase or 
412 placebo, in a double-blind design, during primary PCI. For the RESTORE-MI trial, a key 
413 inclusion criteria is a post-stent index of microcirculatory resistance >32 in the culprit artery, 
414 which signifies incomplete microvascular reperfusion and microvascular dysfunction(26). 
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415 Our analyses raise the possibility that low-dose intracoronary lytic therapy in patients with 
416 STEMI, who have incomplete reperfusion at the end of PCI, may not reduce infarct 
417 pathology and, indeed, may be harmful. Nonetheless, there are important differences in the 
418 design of T-TIME as compared to RESTORE-MI, such as the timing of study drug 
419 administration (before or after stent implantation, respectively) and the lytic agent (alteplase 
420 vs. tenecteplase).
421 Strengths and Limitations
422 Strengths of our study include the double-blind design, high follow up rates with 
423 CMR, core-lab analyses, and the fact that TIMI flow grade immediately pre-study drug 
424 administration was prospectively analysed and was submitted to the data coordination centre 
425 prior to database lock. However, due to the potential for type 1 statistical error, the findings 
426 should be interpreted as exploratory/ hypothesis generating.
427 Although the randomisation was not stratified according to TIMI flow grade, the 
428 randomisation was stratified according to location of MI (anterior vs. non-anterior), which 
429 was the only independent associate of TIMI flow pre-drug. Regression analyses were 
430 adjusted for MI location, to limit the influence of confounding. 
431 Conclusion
432 In STEMI patients with impaired coronary flow at the time of study drug 
433 administration, intracoronary alteplase was associated with increased incidence of MVO and 
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561 Figure Titles and Legends
562 Figure 1. Graphical layout of trial protocol
563 Abbreviations: CMR, cardiovascular magnetic resonance; LGE, late gadolinium 
564 enhancement; MVO, microvascular obstruction; TIMI, Thrombolysis in Myocardial 
565 infarction; STEMI, ST-segment elevation myocardial infarction
566 Figure 2. Study flow diagram
567 CMR (cardiovascular magnetic resonance) follow up is reported according to treatment 
568 received. Abbreviations: MVO, microvascular obstruction; TIMI, Thrombolysis in 
569 Myocardial Infarction.
570 Study Flow Diagram. 
571 Figure 3. Summary of main findings and potential mechanisms
572 A. Forrest plots showing increased MVO and myocardial haemorrhage presence associated 
573 with alteplase vs. placebo in participants with TIMI flow 2 at the time of study drug 
574 administration.
575 B. In participants with reduced antegrade flow in the culprit artery (TIMI flow 2), there may 
576 have been increased microvascular exposure to higher local concentrations of alteplase for 
577 longer. TIMI coronary flow ≤2 may indicate ongoing impaired myocardial reperfusion, due 
578 to extensive microvascular damage. In these circumstances, intracoronary fibrinolysis 
579 appears to worsen MVO and extravasation of erythrocytes, resulting in myocardial 
580 haemorrhage in the infarct core and potentially promotes microvascular thrombosis. An 
581 increase in extravasation of blood into the interstitial space results in external compression of 
582 capillaries with an associated increase in microvascular resistance. This leads to a further 
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583 reduction in myocardial blood flow, and exacerbates myocardial necrosis and capillary 
584 destruction, which promotes further myocardial haemorrhage. 
585 Abbreviations: CI, confidence interval; CMR, cardiovascular magnetic resonance; MVO, 
586 microvascular obstruction; TIMI, Thrombolysis in Myocardial Infarction.
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Table 1. Baseline characteristics, by subgroups of TIMI flow grade (≤2 vs. 3) immediately before study drug administration. Data are reported according 
to treatment received (n=421). Data are mean  SD, or n (%), unless otherwise stated.

















Age 59.5  10.7 59.5  11.3 58.7  11.3 60.3  9.7 61.2  10.0 61.8  10.6 60.1  9.9 61.8  9.5
Male 134 (87%) 44 (88%) 43 (88%) 47 (86%) 224 (84%) 76 (83%) 74 (85%) 74 (84%)
White 143 (93%) 46 (92%) 47 (96%) 50 (91%) 253 (95%) 89 (97%) 81 (93%) 83 (94%)
Asian 9 (6%) 3 (6%) 1 (2%) 5 (9%) 14 (5%) 3 (3%) 6 (7%) 5 (6%)
Body mass index (kg/m2) 28.4  4.8 29.1  5.6 28.1  4.2 27.9  4.4 28.1  5.0 28.1  5.1 28.7  5.2 27.6  4.5
Heart rate at presentation, beats/ min 73.7  17.2 72.1  16.2 70.6  15.3 78.0  18.9 72.1  20.1 73.5  25.6 72.3  16.6 70.3  16.4
Systolic blood pressure at presentation, mmHg 132.4  22.9 128.8  21.5 135.8  23.8 132.7  23.3 134.9  26.6 134.8  28.4 134.3 25.6 135.5  25.8
Diastolic blood pressure at presentation, mmHg 81.1  14.7 77.8  15.1 81.1  14.3 83.4  14.5 80.0  16.0 80.0  17.2 80.6  15.6 79.4  15.1
Infarct location:  
               Anterior

















Hypertension 53 (34%) 18 (36%) 15 (31%) 20 (36%) 82 (31%) 27 (29%) 28 (32%) 27 (31%)
Renal impairment * 1 (1%) 1 (2%) 0 0 5 (2%) 1 (1%) 3 (3%) 1 (1%)
Hypercholesterolemia 40 (26%) 15 (30%) 13 (27%) 12 (22%) 56 (21%) 25 (27%) 14 (16%) 17 (19%)
Diabetes mellitus † 20 (13%) 5 (10%) 9 (18%) 6 (11%) 33 (12%) 13 (14%) 8 (9%) 12 (14%)
Smoking:  
               Current
               Former (stopped >3 months)

























Previous PCI 4 (3%) 1 (2%) 2 (4%) 1 (2%) 14 (5%) 6 (7%) 3 (3%) 5 (6%)
Angina 2 (1%) 1 (2%) 1 (2%) 0 13 (5%) 4 (4%) 4 (5%) 5 (6%)
Previous myocardial infarction 2 (1%) 0 2 (4%) 0 15 (6%) 5 (5%) 3 (3%) 7 (8%)
Stroke/ Transient Ischemic Attack 0 0 0 0 5 (2%) 2 (2%) 1 (1%) 2 (2%)
Peripheral vascular disease 3 (2%) 2 (4%) 1 (2%) 0 9 (3%) 1 (1%) 2 (2%) 6 (7%)
Pre-existing maintenance medication:
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               Aspirin 16 (10%) 6 (12%) 5 (10%) 5 (9%) 47 (18%) 20 (22%) 11 (13%) 16 (18%)
               P2Y712 inhibitor
                              Clopidogrel

















               Statin 31 (20%) 11 (22%) 11 (22%) 9 (16%) 60 (23%) 27 (29%) 17 (20%) 16 (18%)
               Beta blocker 14 (9%) 4 (8%) 6 (12%) 4 (7%) 26 (10%) 12 (13%) 8 (9%) 6 (7%)
               ACE inhibitor or ARB 30 (20%) 8 (16%) 10 (20%) 12 (22%) 43 (16%) 13 (14%) 16 (18%) 14 (16%)
               Mineralocorticoid receptor antagonist 2 (1%) 0 2 (4%) 0 2 (1%) 1 (1%) 0 1 (1%)
Symptom onset to arrival at primary PCI centre, 
median (IQR) hrs
2.2 (1.6, 3.4) 2.2 (1.7, 3.1) 2.1 (1.5, 3.8) 2.5 (1.4, 3.4) 2.2 (1.5, 3.2) 2.0 (1.5, 3.1) 2.2 (1.5, 3.3) 2.2 (1.6, 3.2)
Arrival at primary PCI centre to reperfusion, 
median (IQR) hrs
0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6) 0.4 (0.3, 0.6)
Symptom onset to reperfusion, median (IQR) 
hrs
2.7 (2.1, 3.8) 2.7 (2.1, 3.5) 2.7 (1.9, 4.2) 2.9 (2.1, 3.8) 2.6 (2.0, 3.8) 2.6 (2.0, 3.7) 2.8 (1.9, 4.0) 2.7 (2.0, 3.8)
Initial blood results on admission:
               Hemoglobin, g/dL 147.3  13.2 144.9  15.1 145.7  11.0 151.0  12.5 144.6  13.3 144.0  13.5 145.9  13.6 143.8  12.8
               Platelet count, 103/μL 259.7  61.2 248.7  61.2 273.3  64.6 257.7  56.8 262.6  63.6 254.2  61.0 269.7  75.8 263.9  50.5
               Creatinine, μmol/L 80.5  17.3 83.6  19.2 74.8  12.3 82.7  18.2 80.9  18.1 78.0  17.3 83.4  18.7 81.2  18.2
               eGFR (ml/min/1.73m2) 92.7  21.4 91.1  21.6 96.4  18.4 91.0  23.4 88.9  20.7 90.4  20.9 86.9  20.0 89.3  21.3
* Renal impairment was defined according to the estimated glomerular filtration rate (eGFR), with an eGFR <59 mL/min/1.73 m2 fulfilling the 
criteria for renal impairment.
† Diabetes Mellitus was defined as a history of diet-controlled or treated diabetes. 
Missing: body mass index (calculated as weight in kg divided by height in meters squared), 2; creatinine, 68; eGFR, 68; haemoglobin, 16; 
platelets, 30.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; eGFR, estimated glomerular filtration rate; IQR, 
interquartile range; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. 
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Table 2. Procedure characteristics, by subgroups of TIMI flow grade (≤2 vs. 3) immediately before study drug administration. Data are reported according to treatment 
received (n=421). Data are mean  SD, or n (%), unless otherwise stated.

















Culprit artery: *  
               Left anterior descending
               Circumflex
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Initial TIMI coronary flow grade: * †
               0 (no flow)
               1 (minimal flow)
               2 (slow but complete flow)

































Initial TIMI thrombus grade: * ‡
               0 - 2
               3
               4


































               Aspiration thrombectomy 45 (29%) 12 (24%) 14 (29%) 19 (35%) 74 (28%) 23 (25%) 28 (32%) 23 (26%)
               Balloon angioplasty 109 (71%) 38 (76%) 35 (71%) 36 (66%) 192 (72%) 69 (75%) 59 (68%) 64 (73%)
               Primary stent 0 0 0 0 1 (0.4%) 0 0 1 (1%)
Balloon angioplasty pre-stent 144 (94%) 48 (96%) 46 (94%) 50 (91%) 244 (91%) 83 (90%) 82 (94%) 79 (90%)
Method of study drug delivery:
               Thrombectomy catheter
               Guide catheter

























PCI with stent implantation 152 (99%) 50 (100%) 48 (98%) 54 (98%) 266 (100%) 91 (99%) 87 (100%) 88 (100%)
Post stent dilatation 133 (86%) 48 (96%) 42 (86%) 43 (78%) 233 (87%) 76 (83%) 76 (87%) 81 (92%)
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Total length of stents deployed from 
QCA (mm) *
32.7  14.4 32.9  13.8 35.2  16.2 30.2  13.1 34.5  14.4 34.9  13.3 34.8  14.2 33.9  14.7
QCA reference vessel diameter post-stent 
(mm) *
3.3  0.5 3.2  0.5 3.3  0.6 3.2  0.4 3.2  0.4 3.1  0.4 3.2  0.5 3.2  0.4
Loading with aspirin at first medical 
contact
135 (88%) 44 (88%) 43 (88%) 48 (87%) 230 (86%) 78 (85%) 77 (89%) 75 (85%)
Aspirin loading dose, mg, No/ total (%):
               300

















Additional antiplatelet medication at first 
medical contact:
                None
                 Clopidogrel
                 Ticagrelor

















































Activated clotting time (s) 276.3  89.8 264.3  89.8 303.4  97.6 263.0  78.3 284.0  87.4 280.8  88.5 294.9  88.5 276.1  85.2
Intravenous morphine 114 (74%) 37 (74%) 38 (78%) 39 (71%) 197 (74%) 62 (67%) 64 (74%) 71 (81%)
Inhaled oxygen, No/ total (%) 28/151 (19%) 8/49 (16%) 14/48 (29%) 6/54 (11%) 32/259 (12%) 14/90 (15%) 10/85 (12%) 8/84 (10%)
Glycoprotein IIb/IIIa antagonist, No/ total 
(%)
28/151(19%) 6/49 (12%) 11/48 (23%) 11/54 (20%) 38/259 (15%) 8/90 (9%) 17/85 (20%) 13/84 (16%)
Duration of study drug infusion (min) 6.6  2.0 6.9  2.1 6.5  2.0 6.5  1.9 6.4  1.9 6.2  1.9 6.4  1.9 6.7  2.0
Days from PCI to 2 – 7 days CMR, 
median (IQR)
4.0 (3.0, 6.0) 4.0 (3.0, 5.0) 4.0 (3.0, 6.0) 4.0 (2.8, 6.0) 4.0 (3.0, 6.0) 4.0 (2.8, 5.0) 5.0 (3.0, 6.0) 4.0 (4.0, 6.0)
Days from PCI to 3-month CMR, median 
(IQR)
91.0 (85.0, 98.8) 91.0 (85.0, 97.0) 92.0 (86.0, 99.5) 90.0 (85.0, 99.0) 90.0 (86.0, 95.3) 90.0 (85.8, 94.0) 90.0 (86.0, 96.0) 91.0 (86.0, 97.0)
None of the participants received intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitroprusside.                                        
* The angiographic parameters are based on central laboratory assessments.                                                                                                                                       
† TIMI flow grade is a visual assessment of antegrade coronary artery flow at angiography, graded from 0 (no flow) to 3 (normal flow).                                       
‡ TIMI thrombus grade allows the classification of thrombus burden (greatest dimension) revealed during coronary angiography. TIMI thrombus 
grade 0, no thrombus; 1, possible thrombus, with reduced contrast density, haziness, irregular lesion contour; 2, definite thrombus less than half 
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the vessel diameter; 3, definite thrombus greater than half, but less than 2 vessel diameters; 4, definite thrombus greater than or equal to 2 vessel 
diameters; 5, total occlusion.  
Missing: Activated clotting time, 96; aspirin loading dose, 56; duration of study drug infusion 24; glycoprotein IIb/IIIa antagonist, 11; inhaled 
oxygen, 11. 
Abbreviations: CMR, cardiovascular magnetic resonance; IQR, interquartile range; PCI, percutaneous coronary intervention; QCA, quantitative 
coronary angiography; TIMI, Thrombolysis in Myocardial Infarction. 
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Table 3. Analysis of CMR parameters 2–7 days after primary PCI, by subgroups of TIMI flow grade (≤2 vs. 3) immediately before study drug 
administration (adjusted for MI location [anterior vs. non-anterior]). Treatment effect estimates and interaction with treatment received are shown (see 
footnotes). Data are mean  SD, median [IQR], or n (%), unless otherwise stated.
Treatment group                                      Treatment Effect Treatment Effect
Alteplase 10mg vs. placebo Alteplase 20mg vs. placebo













as a 3-level 
categorical 
variable)




as a 2-level 
categorical 
variable)
MVO presence (n/ total) (a)
     TIMI flow 2 







2.86 (1.19, 6.88) p=0.019
0.61 (0.33, 1.14) p=0.119
2.18 (0.94, 5.04) p=0.069
0.72 (0.39, 1.34) p=0.298
0.013       
2.47 (1.16, 5.22) p=0.018
0.66 (0.39, 1.13) p=0.128
0.005
MVO extent (% of LV mass)† (b)
     TIMI flow 2 







0.31 (-0.24, 0.86) p=0.269
-0.09 (-0.49, 0.31) p=0.661
0.72 (0.19, 1.25) p=0.008
-0.06 (-0.45, 0.34) p=0.777
0.070
0.53 (0.06, 1.00) p=0.027
-0.07 (-0.42, 0.27) p=0.677
0.041
Myocardial haemorrhage presence (n/ total) (a)
     TIMI flow 2 







3.67 (1.42, 9.49) p=0.007
0.64 (0.34, 1.21) p=0.168
2.97 (1.22, 7.27) p=0.017
0.66 (0.35, 1.23) p=0.188
0.004
3.26 (1.44, 7.36) p=0.004
0.65 (0.38, 1.11) p=0.117
0.001
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Myocardial haemorrhage extent (% LV mass)† (c)
     TIMI flow 2 







0.55 (-0.31, 2.42) p=0.562
0.29 (-1.00, 1.58) p=0.656
2.15 (0.45, 3.85) p=0.014
0.11 (-1.16, 1.38) p=0.867
0.120
0.50 (-0.04, 3.04) p=0.057
0.20 (-0.91, 1.31) p=0.726
0.179
Infarct size (% LV mass) (c)
     TIMI flow 2 







3.87 (-1.08, 8.81) p=0.126
-1.35 (-4.92, 2.22) p=0.460
3.87 (-0.90, 8.63) p=0.112
-2.68 (-6.22, 0.86) p=0.138
0.076
3.87 (-0.34, 8.07) p=0.072
-2.03 (-5.09, 1.03) p=0.195
0.026
Myocardial salvage index (c) 
     TIMI flow 2 







-0.06 (-0.16, 0.04) p=0.231
0.02 (-0.05, 0.09) p=0.593
-0.09 (-0.18, 0.01) p=0.080
0.04 (-0.03, 0.11) p=0.254
0.108
-0.07 (-0.16, 0.01) p=0.086
0.03 (-0.03, 0.09) p=0.329
0.049
LV ejection fraction (%) (c)
     TIMI flow 2 







-1.85 (-5.18, 1.48) p=0.276
-0.03 (-2.43, 2.37) p=0.982
-0.67 (-3.88, 2.53) p=0.681
0.40 (-1.98, 2.79), p=0.740
0.681
-1.22 (-4.05, 1.62) p=0.400
0.19 (-1.87, 2.25) p=0.856
0.431
(a) Treatment effect estimates reported as odds ratios between groups, from a logistic regression model.
(b) Treatment effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression 
model.
(c) Treatment effect estimates reported as mean differences between groups, from a linear regression model.
(d) Data analysed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups.
The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive.
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* Missing data: MVO extent, or presence/ absence (n=38); myocardial haemorrhage extent (n=73); myocardial haemorrhage presence/ absence 
(n=55); infarct size, or myocardial salvage index (n=38); LV ejection fraction (n=34)
† Given the high proportion of participants with a 0 value for MVO amount (56% of participants), and myocardial haemorrhage amount (57% of 
participants) the median value for MVO and myocardial haemorrhage was 0 for all groups, while the mean (SDs) are not ideal summaries for 
these data, it has been reported as such for this reason.
Abbreviations: CI, confidence interval; CMR, cardiovascular magnetic resonance; LV, left ventricular; MI, myocardial infarction; MVO, 
microvascular obstruction; TIMI, Thrombolysis in Myocardial Infarction.
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Table 4. Analysis of CMR parameters 3 months after primary PCI, by subgroups of TIMI flow grade (2 vs. 3) immediately before study drug administration 
(adjusted for MI location [anterior vs. non-anterior]). Treatment effect estimates and interaction with treatment received are shown (see footnotes). Data are 
mean ± SD, or median [IQR], unless otherwise stated. 
Treatment Group                    Treatment Effect Treatment Effect













as a 3-level 
categorical 




as a 2-level 
categorical 
variable)
Infarct size (% LV mass) (a)
    TIMI flow 2 







1.11 (-3.61, 5.83) p=0.645
-1.09 (-4.57, 2.39) p=0.539
2.73 (-1.84, 7.3) p=0.242
-0.74 (-4.17, 2.7) p=0.675
0.488    
1.97 (-2.07, 6.01) p=0.339
-0.91 (-3.9, 2.08) p=0.552
0.261
Myocardial salvage index (a)
    TIMI flow 2 







0.0 (-0.09, 0.10) p=0.929
0.02 (-0.05, 0.09) p=0.596
-0.04 (-0.13, 0.06) p=0.437
0.0 (-0.07, 0.07) p=0.940
0.844
-0.02 (-0.10, 0.07) p=0.671
0.01 (-0.05, 0.07) p=0.801
0.623
LV ejection fraction (%) (a)
    TIMI flow 2 







-0.26 (-3.83, 3.32) p=0.889
-1.7 (-4.31, 0.90) p=0.201
-0.69 (-4.15, 2.77) p=0.696
-1.13 (-3.71, 1.44) p=0.389
0.805   
-0.49 (-3.55, 2.57) p=0.754
-1.41 (-3.65, 0.82) p=0.216
0.632
(a) Treatment effect estimates reported as mean differences between groups.
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(b) Data analysed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups.
The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive.
*Missing data: infarct size (n=66); myocardial salvage index (n=72); LV ejection fraction (n=63).
Abbreviations: CI, confidence interval; CMR, cardiovascular magnetic resonance; IQR, inter quartile range; LV, left ventricular; SD, standard deviation; 
MI, myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.































































Confidential: For Review Only
CONFIDENTIAL – EMBARGO APPLIES 40
Supplemental Table 5. Analysis of coagulation variables at 2 hours compared to baseline, by subgroups of TIMI flow grade (2 vs. 3) immediately 
before study drug administration (adjusted for MI location [anterior vs. non-anterior]). Treatment effect estimates and interaction with treatment 
received are shown (see footnotes). Data are median [IQR], unless otherwise stated. 
Treatment Group                    Treatment Effect Treatment Effect













as a 3-level 
categorical 




as a 2-level 
categorical 
variable)
Ratio of fibrinogen at 2 hours relative to baseline (a)
  TIMI flow 2







1.02 (0.95, 1.09) p=0.658
0.98 (0.93, 1.03) p=0.336
0.93 (0.87, 0.99) p=0.021
0.99 (0.94, 1.04) p=0.761
0.032
0.96 (0.91, 1.02) p=0.237
0.98 (0.94, 1.03) p=0.467
0.594
Change in plasminogen (U/dL) at 2 hours relative to baseline (b)
  TIMI flow 2







-4.30 (-8.20, -0.40) p=0.034
-6.10 (-8.90, -3.30) p<0.001
-13.40 (-17.10, -9.60) p<0.001
-10.20 (-13.00, -7.40) p<0.001
0.110
-9.30 (-12.80, -5.80) p<0.001
-8.20 (-10.70, -5.60) p<0.001
0.609
Ratio of fibrin D-dimer at 2 hours relative to baseline (a)
  TIMI flow 2







3.27 (2.47, 4.32) p<0.001
2.86 (2.35, 3.50) p<0.001
3.52 (2.70, 4.59) p<0.001
4.16 (3.41, 5.08) p<0.001
0.213
3.40 (2.67, 4.32) p<0.001
3.46 (2.91, 4.12) p<0.001
0.907
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Ratio of prothrombin fragment F1+2 at 2 hours relative to baseline (a)
  TIMI flow 2







1.46 (1.16, 1.85) p=0.002
1.18 (1.00, 1.39) p=0.057
1.20 (0.96, 1.51) p=0.104
1.20 (1.02, 1.42) p=0.030
0.242
1.31 (1.08, 1.60) p=0.008
1.19 (1.03, 1.38) p=0.018
0.432
Ratio of tissue plasminogen activator at 2 hours relative to baseline (a)
  TIMI flow 2







1.29 (0.95, 1.74) p=0.105
1.14 (0.92, 1.42) p=0.233
1.46 (1.09, 1.94) p=0.011
1.29 (1.04, 1.60) p=0.021
0.761
1.38 (1.06, 1.78) p=0.015
1.21 (1.01, 1.46) p=0.041
0.441
(a) Data analysed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups.
(b) Treatment effect estimates reported as mean differences between groups.
The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive.
*Missing data: change in coagulation parameters at 2 hours relative to baseline (n=80)
Abbreviations: IQR, inter quartile range; MI, myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.
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Figure 1. Graphical layout of trial protocol 
127x98mm (300 x 300 DPI) 
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Figure 2. Study flow diagram 
137x152mm (300 x 300 DPI) 
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Figure 3. Summary of main findings and potential mechanisms 
117x152mm (300 x 300 DPI) 
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Eligibility Criteria 8 
Patients with a clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI) were 9 
eligible for randomisation according to the following eligibility criteria: 10 
Inclusion 11 
• Acute MI (symptom onset ≤ 6 hours) with persistent ST-segment elevation or recent left bundle 12 
branch block 13 
• Coronary artery occlusion (TIMI [Thrombolysis in Myocardial Infarction] coronary flow grade 14 
0 or 1), or impaired coronary flow (TIMI coronary flow grade 2, slow but complete filling) in 15 
the presence of definite angiographic evidence of thrombus (TIMI grade 2 or more) 16 
• Proximal-mid culprit lesion location in a major coronary artery (i.e. the right, left anterior 17 
descending, intermediate, or circumflex artery) 18 
• Radial artery access 19 
• Successful coronary reperfusion (TIMI coronary flow grade ≥2) pre-stent achieved prior to 20 
randomisation. 21 
• Informed consent, i.e. only patients who were sufficiently well to understand the information 22 
about the study, as described by the attending cardiologist, were eligible to participate.  23 
Exclusion 24 
• Normal flow in the culprit coronary artery at initial angiography (TIMI grade 3) 25 
• Functional coronary collateral supply (Rentrop grade 2/3) to the culprit artery 26 
• Previous infarction in the culprit artery (known or suspected clinically, e.g. wall motion 27 
abnormality revealed by echocardiography) 28 
• Cardiogenic shock (Killip Class IV) 29 
• Multivessel percutaneous coronary intervention (PCI) intended before the day 2-7 30 
cardiovascular magnetic resonance (CMR) scan 31 
• Estimated body weight <60 kg 32 
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• Non-cardiac co-morbidity with expected survival <1 year 33 
• Contra-indication to contrast-enhance CMR imaging 34 
• Pacemaker, or implantable defibrillator 35 
• Known impaired renal function (estimated glomerular filtration rate <30ml/min) 36 
• Significant bleeding disorder either at present or within the past 6 months 37 
• Known haemorrhagic diathesis 38 
• Patient with current concomitant oral anticoagulation therapy (international normalised ratio 39 
>1.3), including apixaban, dabigatran and rivaroxaban 40 
• Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal 41 
surgery) 42 
• Severe hypertension (blood pressure >180/110 mmHg) not controlled by medical therapy 43 
• Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 3 months 44 
(this includes any trauma associated with the current acute MI) 45 
• Recent head trauma (<2 months) 46 
• Prolonged cardiopulmonary resuscitation (>2 minutes) within the past 2 weeks 47 
• Acute pericarditis and/ or subacute bacterial endocarditis 48 
• Acute pancreatitis 49 
• Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension 50 
(oesophageal varices) and active hepatitis 51 
• Active peptic ulceration 52 
• Arterial aneurysm and known arterial/ venous malformation 53 
• Neoplasm with increased bleeding risk 54 
• Any known history of haemorrhagic stroke, or stroke of unknown origin 55 
• Known history of ischaemic stroke, or transient ischemic attack in the preceding 6 months 56 
• Dementia 57 
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• Hypersensitivity to gentamicin, or natural rubber 58 
• Incapacity, or inability to provide informed consent 59 
• Previous randomisation to this study, or participation in a study with an investigational drug, or 60 
medical device within 90 days prior to randomisation 61 
• Women of child bearing potential (i.e. pre-menopausal), or breast feeding 62 
• Requirement for immunosuppressive therapy at any time during the preceding 3 months. This 63 
would include corticosteroids (but not inhaled or topical), drugs used following transplantation 64 
(e.g tacrolimus, cyclosporine), anti-metabolite therapies (e.g. mycophenolic acid, azathioprine, 65 
leflunomide and immunomodulators including biologics (e.g. adalimumab, or etanercept) and 66 
disease modifying anti-rheumatic drugs. This list is not exhaustive. 67 
• Active or prophylactic treatment with oral, or parenteral antibiotic, antifungal, or antiviral 68 
therapy, to prevent or treat infection 69 
• Any anti-cancer treatment (excluding surgery as this is covered above) at any time during the 70 
preceding 3 months, including chemotherapy, radiotherapy, and treatment with biologics, such 71 
as Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (e.g. bevacizumab, 72 
pazopanib). This list is not exhaustive. 73 
• Any significant concurrent, or recent condition(s) not listed above that in the opinion of the 74 
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Standard Care 83 
 Standard care for coronary reperfusion was with balloon angioplasty, or aspiration 84 
thrombectomy for thrombus-containing lesions. A coronary balloon diameter (mm) vs. lumen diameter 85 
(mm) relationship of <1:1 and a low inflation pressure were recommended to minimise thrombus 86 
embolization. The balloon angioplasty was intended to stabilise the thrombotic lesion and prevent vessel 87 
re-occlusion prior to stent implantation. Anti-thrombotic therapy included oral anti-platelet drugs and 88 
intravenous heparin (5000 IU, or as per standard practice) at the first medical contact. The target 89 
activated clotting time (ACT) was 250s. 90 
Interventions 91 
 After initial balloon angioplasty/ thrombus aspiration, the participants were randomised using 92 
an interactive voice response-based system, and then received the allocated intervention. The study drug 93 
(placebo, alteplase 10mg, or alteplase 20mg) was manually infused before stent implantation. The drug 94 
was reconstituted by the clinical staff using 20ml of sterile water for injection. The cardiologist then 95 
infused the solubilised drug over 5-10 minutes directly into the culprit artery, proximal to the culprit 96 
lesions, using either an intracoronary catheter or the guiding catheter if selectively engaged.  97 
Angiogram Acquisition & Analysis Methods 98 
Coronary angiograms were acquired during emergency care with cardiac catheter laboratory X-99 
ray and information technology equipment. The angiograms were analysed using post-processing 100 
software (QAngio® XA Medis, Leiden, NL.) by experienced investigators who were blinded to 101 
treatment allocation. Catheter calibration was performed using the catheter calibration function on 102 
MEDIS QAngio. For each lesion, a view perpendicular to the long axis of the vessel was used in order 103 
to avoid foreshortening and overlap of branches. The single plane projection showing the best opacified 104 
and most severe lesion with minimal foreshortening and minimal branch overlap was selected. 105 
Feedback was provided to sites on the quality and completeness of the angiograms. 106 
 107 
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TIMI Coronary Flow Grade 108 
The TIMI coronary flow grade was assessed using the following definitions(1): 109 
TIMI coronary flow grade Definition 
0 No flow 
1 Minimal flow past obstruction 
2 Slow (but complete) filling and slow clearance 
3 Normal flow and clearance 
 110 
TIMI Myocardial Perfusion Grade 111 
TIMI myocardial perfusion grade provides a score for ground-glass appearance (‘blush’) of the 112 
contrast entering the microvasculature and contrast washout. TIMI myocardial perfusion grade was 113 
assessed according to the following definitions(2): 114 
TIMI myocardial perfusion grade Definition 
0 Minimal or no myocardial blush in the distribution 
of the culprit artery. 
 
1 Myocardial blush is present in the distribution of 
the culprit artery. But there is incomplete 
clearance of dye between injections (with ~ 30 
seconds between injections). 
 
2 Myocardial blush is present in the distribution of 
the culprit artery. But there is slow contrast 
entry into the microvasculature and slow clearance 
of contrast. Specifically, blush is strongly persistent 
(i.e. either does not or only minimally diminishes in 
intensity) beyond 3 cardiac cycles after injection. 
 
3 Myocardial blush is present in the distribution of 
the culprit artery, with normal entry and exit 
of dye (mild/ moderate persistence of dye beyond 3 
cardiac cycles, but notably reduced after 3 cardiac 
cycles). Blush that is only mild intensity throughout 3 
cardiac cycles after injection (washout phase), but fades 
minimally is also classified as grade 3.  
 115 
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TIMI Frame Count 116 
     The TIMI frame count represents the amount of time (in frames) for contrast dye to reach 117 
a standardized distal landmark.(2) If the culprit vessel was the left anterior descending artery 118 
the frame count was divided by 1.7 (correcting for longer vessel length). 119 
TIMI Coronary Thrombus Grade 120 
     Thrombus burden revealed during coronary angiography was classified according to the 121 
TIMI thrombus grade(3): 122 
Thrombus grade Definition 
0 No angiographic characteristics of thrombus are present 
 
1 Possible thrombus is present, with reduced contrast density, 
haziness, irregular lesion contour, or a smooth convex 
‘meniscus’ at the site of total occlusion suggestive but not 
diagnostic of thrombus 
 
2 Definite thrombus, with greatest dimensions ≤ half the vessel 
diameter 
 
3 Definite thrombus but with greatest long axis dimension >1/2 
but <2 vessel diameters 
 
4 Definite thrombus, with the largest dimension ≥2 vessel 
diameters 
 
5 Total occlusion 
 123 
Lesion Characterisation 124 
     The culprit lesions were assessed for complexity using the modified American College of 125 
Cardiology/ American Heart Association score, which characterises coronary lesions as type 126 
A, B1 (one characteristic of a type B lesion), B2 (two or more characteristics of a type B 127 
lesion) and C.(4) 128 
      The culprit lesions were also assessed for complexity using a 6-point plaque 129 
characterisation score,(5) comprising:  130 
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(i) Intraluminal filling defect consistent with thrombus 131 
(ii) Ulcerated appearance, for example hazy contour, and/ or apple-core appearance 132 
(iii) Irregularity of vessel borders 133 
(iv) TIMI flow <3 beyond the lesion 134 
(v) Moderate to severe calcification, i.e. calcification in more than one cine, outlining 135 
the full lumen 136 
(vi) Lesion at a bifurcation point 137 
CMR Acquisition and Analysis 138 
CMR was performed using 1.5-T platforms (Siemens MAGNETOM Avanto, 139 
Erlangen, Germany and Philips Intera, Best, The Netherlands). The imaging protocol 140 
followed a standard operating procedure that included planning and localisers, T1-mapping, 141 
T2*-mapping, cine CMR with steady-state free precession (SSFP), and late gadolinium 142 
enhancement imaging 10 – 15 minutes after administration of contrast media.(6) The scan 143 
acquisitions were spatially co-registered and also included different slice orientations to 144 
enhance diagnostic confidence. 145 
The intravenous contrast agent used in this study was gadobutrol (Gadovist®, Bayer: 146 
1.5 mmol/ml solution for injection), which was administered in two doses. The first dose 147 
injection (0.05 mmol/kg) was given to initiate the first-pass of contrast. The second dose (0.1 148 
mmol/kg) was given immediately after the first-pass. Therefore, the total dose of gadobutrol 149 
was 0.15 mmol/kg.  150 
SSFP cine breath-hold sequences (with parallel imaging acceleration) were used. The 151 
heart was imaged in multiple parallel SAX planes 8-mm thick, separated by 2mm gaps, 152 
equating to approximately 10 slices and 30 cardiac phases. The CMR analyses were 153 
undertaken using Medis® Suite MR (Medis, Leiden, NL), by two trained investigators who 154 
were blinded to treatment allocation.  155 
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Late Gadolinium Enhancement  156 
Late microvascular obstruction (MVO) was imaged 10-15 minutes after intravenous 157 
Gadovist contrast administration, using in general a motion corrected T1-weighted phase-158 
sensitive inversion recovery radiofrequency pulse sequence. A full stack, aligned to T2* 159 
scans (or cines) and 3 long axis views (vertical long axis, horizontal long axis and 3 chamber 160 
view) were acquired. 161 
 MVO was defined as a dark zone on early gadolinium enhancement imaging 1, 3, 5 162 
and 7-minutes post-contrast injection that remained present within an area of late gadolinium 163 
enhancement at 15 minutes. The endocardial and epicardial borders were contoured. The 164 
myocardial mass (grams) of the dark zone was quantified by manual delineation and 165 
expressed as a percentage of total left ventricular (LV) mass. 166 
Infarct Size 167 
The presence of acute infarction was established based on abnormalities in cine wall 168 
motion, rest first-pass myocardial perfusion, and late gadolinium enhancement imaging in 169 
two imaging planes. The myocardial mass of late gadolinium (grams) was quantified using 170 
computer assisted planimetry and the territory of infarction was delineated using a 5 standard 171 
deviation method and expressed as a percentage of total LV mass. Typical late gadolinium 172 
enhancement and MVO imaging parameters with phase sensitive inversion recovery: matrix 173 
192 x 256 pixels; flip angle 25o; TE 3.36 ms; bandwidth 130 Hz/pixel; echo spacing 8.7ms 174 
and trigger pulse 2. The voxel size is 1.8 x 1.3 x 8 mm. Inversion times i dividually adjusted 175 
to optimize nulling of apparently normal myocardium (typical values, 200 to 300ms). 176 
Myocardial Oedema 177 
The presence of myocardial oedema was established based on an area of increased 178 
signal intensity on the SSFP cine images (acquired two minutes after gadolinium contrast 179 
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injection). The myocardial mass was calculated by manual delineation in end-diastole and 180 
end-systole. The values were averaged and expressed as a percentage of LV mass.(6) 181 
Myocardial Salvage 182 
Myocardial salvage was calculated by subtraction of percent infarct size from percent 183 
area-at risk, as reflected by the extent of oedema. The myocardial salvage index was 184 
calculated by dividing the myocardial salvage area by the initial area-at-risk. 185 
Myocardial Haemorrhage 186 
On the T2* parametric maps, a threshold of 20ms was applied. A region of reduced 187 
signal intensity within the infarcted area, with a T2* value of <20 ms(7)(8) was considered to 188 
confirm the presence of myocardial haemorrhage. The area was manually delineated and 189 
expressed as % LV mass. 190 
Local Hospital Blood Sample Handling 191 
Blood samples were measured when site logistics permitted. The sampling time-192 
points were 0, 2 and 24 hours post-PCI. Blood samples were collected into 0.109M sodium 193 
citrate (for haemostasis assays), or EDTA (Troponin). The blood samples were centrifuged 194 
locally and plasma separated and frozen within 2 hours of sampling. Frozen plasma samples 195 
were subsequently transported on dry ice for central laboratory analysis in the department of 196 
Haematology, Macewan Building, 16 Alexandra Parade, Glasgow Royal Infirmary, G31 197 
2ER. Plasma samples were stored at -80oC until analysis, with residual samples being 198 
transferred to the Glasgow Biorepository for storage at the end of the study.  199 
Central Laboratory Analysis for Troponin T 200 
EDTA plasma samples were stored at -80oC in the Glasgow Royal Infirmary until 201 
batch analysis at the end of the study. The biochemical analyses were performed in the 202 
British Heart Foundation Glasgow Cardiovascular Research Centre. 203 
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EDTA plasma samples were stored to analyse high-sensitivity cardiac troponin T 204 
(ng/ml) on first thaw. Serial measurements of troponin T using the Roche high-sensitivity 205 
assay were used to provide a biochemical measurement of infarct size (area-under-the-curve).  206 
For measurement of high sensitivity cardiac troponin T, we used an automated 207 
method (e411, Roche Diagnostic, Burgess Hill, U.K.) calibrated and quality controlled using 208 
the manufacturers reagents. We also participated in the National External Quality Assurance 209 
Scheme (NEQAS). The lower limit of detection of Troponin T is 0.003 ng/ml and the 99th 210 
percentile value in a healthy subpopulation is 0.0014 ng/ml (Roche Diagnostics, data on file). 211 
The between-assay coefficient of variations were 2.2% and 4.2% for control materials with 212 
mean Troponin T concentrations of 2.098 ng/ml and 0.00027 ng/ml, respectively.  213 
Central Laboratory Analysis for Coagulation Parameters 214 
 The coagulation parameters measured in this study included fibrinogen and 215 
plasminogen (both measures of coagulation and systemic fibrinolysis), fibrin D-Dimer (a 216 
measure of fibrin lysis), tissue plasminogen activator (tPA) (a measure of endogenous tPA 217 
and any circulating alteplase) and prothrombin fragment F1+2 (a measure of thrombin 218 
activation). A depletion of fibrinogen and plasminogen following thrombolysis correlates 219 
with systemic fibrinolysis and may correlate with bleeding risk. Prothrombin fragment F1+2 220 
is a measure of thrombin activation and correlate with the (undesired) procoagulant effect of 221 
thrombolysis. Prothrombin fragment F1+2 is depressed by anti-coagulants administered 222 
before and during PCI.  223 
 Standard laboratory assays (Fibrinogen by Clauss method; high sensitivity Fibrin D-224 
Dimer by latex immunoassay; and Plasminogen Activity by chromogenic assay were 225 
performed on an IL TOP700 analyser using HemosIL
Ò
 reagents (Instrumentation Laboratory 226 
Company, Bedford, U.S.). The fibrinogen Clauss assay had a normal reference rages 170 – 227 
4.0 g/L (internally derived) and an inter-assay coefficient of variation of 5.8% and 7.7% for 228 
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low control samples with mean concentrations of 2.92 g/L and 2.22 g/L respectively. The 229 
fibrin D-Dimer assay had a normal reference range <0.230 µg/ml (manufacturer derived), and 230 
an inter-assay coefficient of variation of 11.7% and 5.2% for control samples with mean 231 
concentrations of 0.343 µg/ml and 0.770 µg/ml respectively. The plasminogen activity assay 232 
had a normal reference rage 80 – 133 U/dL (manufacturer derived), and an inter-assay 233 
coefficient of variation of 2.1% and 1.8% for control samples with mean concentrations of 234 
95.4 U/dL and 29.6 U/dL, respectively. 235 
 Non-standard laboratory ELISA assays (tissue plasminogen activator [tPA] and 236 
Prothrombin fragment F1+2 antigen levels) were performed on a TECAN Sunrise 237 
spectrophotometer (Labtech International Ltd, U.K.) using Zymutest tPA Antigen (Hyphen 238 
BioMed, Neuville-sur-oise France) and Enzygnost F1+2 Mono (Siemens, Marburg, 239 
Germany) commercial kits respectively. The tPA antigen assay had a normal reference range 240 
<10 ng/ml (manufacturer derived), and an inter-assay coefficient of variation of 4.7% and 241 
11% for control samples with mean concentrations of 11.0 ng/ml and 3.1 ng/ml, respectively. 242 
The F1+2 assay had a normal reference rage 69 – 229 pmol/L (manufacturer derived) and an 243 
inter-assay coefficient of variation of 7.9% for a normal control sample with a mean 244 
concentration of 97.6 pmol/L. 245 
Trial Management 246 
There was a Trial Management Group for operational activity, an independent Data 247 
and Safety Monitoring Committee and a Trial Steering Committee to coordinate the trial and 248 
liaise with the Sponsor and Trials Unit. Each committee had a charter that was established 249 
before enrolment started.  250 
 The independent Data and Safety Monitoring Committee met before the enrolment 251 
began, and twice again during the active phase of the trial. This committee had responsibility 252 
for potentially recommending early discontinuation of the entire study or an individual arm, 253 
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because of safety concerns or due to futility. The funder, the Efficacy and Mechanism 254 
Evaluation (EME) program of the National Institute for Health Research (NIHR) required an 255 
interim analysis for futility and also specified the criteria. Following a prespecified futility 256 
analysis, performed when 40% of the trial population had reached 3 months follow-up, the 257 
Data and Safety Monitoring Committee recommended that enrolment into the T-TIME trial 258 
should be discontinued on December 21 2017. 259 
 The Robertson Centre for biostatistics within the Glasgow Clinical Trials Unit 260 
provided the trial-specific electronic data collection system, acted as an independent 261 
coordination centre for randomisation and data management. The trial was approved by the 262 
National Research Ethics Service (reference 13/WS/0119). The clinical trial registration 263 
number is NCT02257294 and the trial was co-sponsored by the University of Glasgow and 264 
greater Glasgow and Clyde Health Board, NHS Scotland. The sponsor undertook feasibility 265 
assessments at each site, visits were undertaken in all of the sites. All serious adverse events 266 
were prospectively reported to the Pharmacovigilance Unit.267 
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Supplemental Table 1. Additional procedure characteristics, by subgroups of TIMI flow grade (≤2 vs. 3) immediately before study drug administration. 
Data are reported according to treatment received (n=421). Data are mean ± SD, or n (%). 
 Impaired coronary flow (TIMI flow £ 2) 
 
  Normal coronary flow (TIMI 3 flow) 
















American Heart Association culprit lesion 
type: *   
               B2 

































Culprit lesion plaque characterisation 
score: † * 
               2 
               3 
               4 
               5 


























































QCA lesion length pre-drug (mm) * 25.5 ± 11.2 26.7 ± 11.6 27.4 ± 12.4 22.7 ± 9.3   27.2 ± 11.3 26.7 ± 10.6 27.6 ± 11.6 27.5 ± 11.8 
Total number of stents deployed: 
               0 
               1 
               2 









































* The angiographic parameters are based on central laboratory assessments.  
† The plaque characterisation score comprised one point for each of: intraluminal thrombus, ulceration, irregularity of vessel borders, TIMI flow 
<3 beyond the lesion, moderate-severe calcification and bifurcation. 
Abbreviations: QCA, quantitative coronary angiography.  
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Supplemental Table 2. Analysis of CMR derived LV end-diastolic and end-systolic volumes, by subgroups of TIMI flow grade (£2 vs. 3) immediately before 
study drug administration (adjusted for MI location [anterior vs. non-anterior]). Data are median [IQR]. 
 Treatment Group                    Treatment Effect Interaction 
p-value 
(treatment 




Treatment Effect Interaction 
p-value 
(treatment 














Alteplase 10mg vs placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
CMR parameters 2-7 days after primary PCI          
LV end-diastolic volume (ml)             
TIMI flow £2 
 
174.2 [153.9, 214.1] 
 
177.3 [163.9, 212.3] 
 
161.6 [142.6, 200.0] 
 
1.02 (0.93, 1.12) p=0.721 
  
0.94 (0.86, 1.03) p=0.171 
  0.340 
  




TIMI 3 flow  162.2 [141.8, 190.1] 176.5 [155.5, 205.8] 170.5 [136.6, 194.3] 1.08 (1.01, 1.16) p=0.021  1.02 (0.95, 1.09) p=0.601    1.05 (0.99, 1.11) p=0.105 
LV end-systolic volume (ml)            
TIMI flow £2 
 
96.2 [80.2, 118.9] 
 
105.3 [85.6, 124.3] 
 
95.5 [80.8, 113.6] 
 
0.0 (-0.85, 0.86) p=0.993  0.73 (-0.08, 1.54) p=0.080  
0.261     
  0.40 (-0.32, 1.13) p=0.277 
0.284    
TIMI 3 flow  90.2 [75.9, 108.0] 92.9 [79.0, 113.5] 92.5 [72.3, 109.0] -0.12 (-0.80, 0.57) p=0.738  -0.10 (-0.80, 0.60) p=0.778    -0.11 (-0.70, 0.49) p=0.72 
CMR parameters 3 months after primary PCI          
LV end-diastolic volume (ml)           
TIMI flow £2 
 
170.2 [158.8, 207.1] 
 
170.0 [152.9, 206.4] 
 
174.0 [150.5, 195.1] 
 
1.01 (0.91, 1.12) p=0.796 
  
0.95 (0.86, 1.05) p=0.349 
  0.567 
  
0.98 (0.90, 1.07) p=0.673 
 0.281 
TIMI 3 flow  157.9 [138.9, 188.5] 173.6 [153.7, 205.6] 162.9 [140.4, 194.3] 1.08 (1.00, 1.16) p=0.045  1.01 (0.94, 1.08) p=0.847    1.04 (0.98, 1.11) p=0.213 
LV end-systolic volume (ml)           
TIMI flow £2 
 
81.6 [72.8, 114.7] 
 
88.9 [71.4, 116.5] 
 
92.1 [71.5, 110.1] 
 
1.03 (0.88, 1.20) p=0.729 
 




  1.01 (0.88, 1.15) p=0.923 
 0.508 
TIMI 3 flow 77.5 [60.7, 99.5] 85.9 [71.7, 103.3] 78.5 [65.8, 102.1] 1.10 (0.99, 1.23) p=0.085  1.03 (0.92, 1.15) p=0.640    1.06 (0.97, 1.17) p=0.210 
Data analysed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups.  
The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive. 
* Missing data: LV volumes 2 – 7 days after primary PCI (n=34), LV volumes 3 months after primary PCI (n=63). 
* Missing data: LV volumes 2 – 7 days after primary PCI (n=34), LV volumes 3 months after primary PCI (n=63). 
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Supplemental Table 3. Analysis of selected CMR parameters 2-7 days after primary PCI, by subgroups of TIMI flow grade (£2 vs. 3) immediately before 
study drug administration, and by subgroups of MI location (anterior [n=187], non-anterior [n=234]). Treatment effect estimates and interaction with 
treatment received are shown (see footnotes). Data are mean ± SD, or n (%), unless otherwise stated.  
 Treatment Group                    Treatment Effect Interaction 
p-value 
(treatment 




Treatment Effect Interaction 
p-value 
(treatment 














Alteplase 10mg vs placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
MVO presence (n/ total) (a)            
Anterior-MI:          TIMI flow £2 8/23 (34.8) 11/22 (50.0) 15/27 (55.6) 1.88 (0.57, 6.21) p=0.304  2.34 (0.75, 7.37) p=0.145  
0.354    
  2.12 (0.77, 6.13) p=0.151 
0.150     
                      TIMI 3 flow  19/36 (52.8) 16/34 (47.1) 15/31 (48.4) 0.80 (0.31, 2.03) p=0.633  0.84 (0.32, 2.19) p=0.720    0.82 (0.36, 1.84) p=0.625 
Non-anterior MI:    TIMI flow £2 7/21 (33.3) 14/20 (70.0) 11/22 (50.0) 4.67 (1.25, 17.44) p=0.022  2.00 (0.58, 6.87) p=0.271  
0.014     
  2.94 (0.98, 8.81) p=0.054 
0.012     
                        TIMI 3 flow 22/49 (44.9) 13/46 (28.3) 18/52 (34.6) 0.48 (0.21, 1.14) p=0.095  0.65 (0.29, 1.45) p=0.292    0.57 (0.28, 1.15) p=0.116 
MVO extent (% LV mass)† (b)            
Anterior-MI:            TIMI flow £2 3.7 ± 7.4 2.5 ± 3.4 6.3 ± 8.0 0.0 (-0.85, 0.86) p=0.993  0.73 (-0.08, 1.54) p=0.080  
0.261     
  0.40 (-0.32, 1.13) p=0.277 
0.284    
                                 TIMI 3 flow  3.0 ± 4.1 2.9 ± 4.6 3.1 ± 5.6 -0.12 (-0.80, 0.57) p=0.738  -0.10 (-0.80, 0.60) p=0.778    -0.11 (-0.70, 0.49) p=0.72 
Non-anterior MI:     TIMI flow £2 1.4 ± 2.9 3.1 ± 4.5 4.2 ± 6.5 0.65 (-0.07, 1.37) p=0.079  0.71 (0.00, 1.41) p=0.050  
0.156     
  0.68 (0.07, 1.29) p=0.031 
0.053     
                                 TIMI 3 flow 1.5 ± 2.6 2.1 ± 4.9 1.8 ± 3.3 -0.07 (-0.54, 0.40) p=0.775  -0.02 (-0.48, 0.44) p=0.922    -0.04 (-0.45, 0.36) p=0.828 
Myocardial haemorrhage presence (n/ total) (a)           
Anterior-MI:            TIMI flow £2 7/21 (33.3) 10/19 (52.6) 15/27 (55.6) 2.22 (0.62, 7.98) p=0.221  2.50 (0.77, 8.16) p=0.129  
0.245    
  2.38 (0.83, 7.32) p=0.114 
0.102     
                                 TIMI 3 flow  17/34 (50.0) 15/33 (45.5) 12/29 (41.4) 0.83 (0.32, 2.18) p=0.710  0.71 (0.26, 1.92) p=0.494    0.77 (0.33, 1.79) p=0.544 
Non-anterior MI:     TIMI flow £2 4/19 (21.1) 12/19 (63.2)  11/22 (50.0) 6.43 (1.62, 30.35) p=0.012  3.75(0.99, 16.56) p=0.061  
0.007    
  4.79 (1.45, 19.13) p=0.015 
0.003     
                                 TIMI 3 flow  22/48 (45.8) 13/43 (30.2) 18/52 (34.6) 0.51 (0.22, 1.22) p=0.129  0.63 (0.28, 1.40) p=0.254    0.57 (0.28, 1.17) p=0.124 
Myocardial haemorrhage extent (% LV mass)† (c)           
Anterior-MI:            TIMI flow £2 2.9 ± 7.1 2.8 ± 4.0 4.6 ± 6.4 -0.08 (-3.22, 3.05) p=0.959  1.74 (-1.10, 4.64) p=0.230  
0.472  
  1.01 (-1.59, 3.61) p=0.447 
0.752  
                           TIMI 3 flow 1.6 ± 3.0 2.0 ± 3.4 2.2 ± 5.2 0.39 (-2.08, 2.87) p=0.757  0.55 (-2.01, 3.10) p=0.676    0.46 (-1.71, 2.64) p=0.677 
Non-anterior MI:      TIMI flow £2 0.4 ± 1.1 1.6 ± 2.5 2.9 ± 4.9 1.21 (-0.94, 3.36) p=0.272  2.52 (0.56, 4.47) p=0.012  
0.072     
  1.99 (0.23, 3.75) p=0.028 
0.067    
                            TIMI 3 flow 1.3 ± 2.7  1.6 ± 3.8  1.1 ± 2.8  0.28 (-1.04, 1.60) p=0.679  -0.16 (-1.43, 1.11) p=0.804    0.04 (-1.08, 1.16) p=0.944 
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Infarct size (% LV mass) (c)     
Anterior-MI:              TIMI flow £2       33.4 ± 17.0 37.6 ± 11.5 35.3 ± 15.4 4.13 (-3.97, 12.23) p=0.319  1.91 (-5.80, 9.61) p=0.628  
0.382    
  2.91 (-3.94, 9.75) p=0.407 
0.180     
                                   TIMI 3 flow 331. ± 12.7 31.3 ± 12.0 28.4 ± 14.5 -1.75 (-8.24, 4.75) p=0.598  -4.71 (-11.36, 1.95) p=0.167    -3.16 (-8.79, 2.47) p=0.272 
Non-anterior MI:       TIMI flow £2 22.3 ± 11.4 25.8 ± 11.3 28.5 ± 8.3 3.57 (-2.35, 9.49) p=0.238  6.23 (0.45, 12.01) p=0.036  
0.097    
  4.96 (-0.08, 10.01) p=0.055 
0.045     
                               TIMI 3 flow 20.8 ± 9.8 19.8 ± 8.8 19.5 ± 9.4 -1.06 (-4.95, 2.83) p=0.595  -1.34 (-5.11, 2.43) p=0.488    -1.21 (-4.51, 2.1) p=0.475 
Myocardial salvage index (c)           
Anterior-MI:               TIMI flow £2 0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 -0.09 (-0.22, 0.04) p=0.197  -0.05 (-0.18, 0.08) p=0.434  
0.217     
  -0.07 (-0.18, 0.04) p=0.241 
0.085     
                               TIMI 3 flow 0.3 ± 0.2 0.4 ± 0.2 0.4 ± 0.3 0.05 (-0.06, 0.15) p=0.402  0.08 (-0.03, 0.18) p=0.173    0.06 (-0.03, 0.15) p=0.202 
Non-anterior MI:        TIMI flow £2 0.4 ± 0.3 0.3 ± 0.3 0.2 ± 0.2 -0.03 (-0.18, 0.12) p=0.676  -0.13 (-0.28, 0.01) p=0.077  
0.213      
  -0.08 (-0.21, 0.04) p=0.196 
0.231       
                                TIMI 3 flow 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2   0.00 (-0.10, 0.10) p=0.990  0.02 (-0.08, 0.11) p=0.740    0.01 (-0.07, 0.09) p=0.836 
LV ejection fraction (%) (c)           
Anterior-MI:               TIMI flow £2 38.8 ± 12.6 39.8 ± 8.0 40.8 ± 8.8 0.96 (-4.10, 6.02) p=0.711  2.03 (-2.83, 6.9) p=0.414  
0.969 
  1.54 (-2.77, 5.84) p=0.485 
0.896 
                                 TIMI 3 flow 41.0 ± 8.4 41.3 ± 7.7 43.2 ± 7.0 0.29 (-3.81, 4.39) p=0.890  2.12 (-2.08, 6.32) p=0.323    1.16 (-2.39, 4.71) p=0.522 
Non-anterior MI:        TIMI flow £2 48.4 ± 3.2 43.4 ± 9.5 44.7 ± 8.4 -4.97 (-9.35, -0.59) p=0.027  -3.69 (-7.92, 0.54) p=0.089  
0.199      
  -4.29 (-8.00, -0.57) p=0.025 
0.093     
                                TIMI 3 flow 47.4 ± 6.3 47.2 ± 6.1 46.8 ± 8.2 -0.25 (-3.10, 2.59) p=0.861  -0.69 (-3.47, 2.09) p=0.627    -0.48 (-2.91, 1.94) p=0.697 
(a) Treatment effect estimates reported as odds ratios between groups, from a logistic regression model. 
(b) Treatment effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression 
model. 
(c) Treatment effect estimates reported as mean differences between groups, from linear regression. 
The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive. 
 
* Missing data: MVO extent, or presence/ absence (n=38); myocardial haemorrhage extent (n=73); myocardial haemorrhage presence/ absence 
(n=55); infarct size, or myocardial salvage index (n=38); LV ejection fraction (n=34) 
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† Given the high proportion of participants with a 0 value for MVO amount (56% of participants), and myocardial haemorrhage amount (57% of 
participants) the median value for MVO and myocardial haemorrhage was 0 for all groups, while the mean (SDs) are not ideal summaries for 
these data. It has been reported as such for this reason. 
Abbreviations: CI, confidence interval; CMR, cardiovascular magnetic resonance; LV, left ventricular; MI, myocardial infarction; MVO, 
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Supplemental Table 4. Baseline characteristics according to availability of MVO data (complete vs. missing). Data are mean ± 
SD, or n (%), unless otherwise stated. 
 MVO data available 
(n=383) 
MVO data missing 
(n=38) 
 P-value  
Age  60.5 ± 10.0 61.9 ± 12.8 0.501 
Male 327 (85%) 31 (82%) 0.482 
White 359 (94%) 37 (97%) 0.715 
Asian 22 (6%) 1 (3%) 0.710 
Body mass index (kg/m2) 28.1 ± 4.9 29.1 ± 4.9 0.235 
Heart rate at presentation, beats/ min 72.4 ± 19.1 75.2 ± 18.6  0.396 
Systolic blood pressure at presentation, mmHg 133.8 ± 25.1 135.4 ± 27.3 0.730 
Diastolic blood pressure at presentation, mmHg 81.1 ± 14.7 80.0 ± 16.0 0.683 
Anterior myocardial infarction 170 (44%) 15 (40%) 0.610 
Hypertension 117 (31%) 18 (47%) 0.044 
Hypercholesterolemia 83 (22%) 13 (34%) 0.103 
Diabetes mellitus † 45 (12%) 8 (21%) 0.120 
Smoking:   
               Current 
               Former (stopped >3 months) 













Pre-existing maintenance medication:    
               Aspirin 54 (14%) 9 (24%) 0.148 
               Statin 77 (20%) 14 (37%) 0.023 
               Beta blocker 33 (9%) 7 (18%) 0.074 
               ACE inhibitor or ARB 62 (16%) 11 (29%) 0.069 
Symptom onset to arrival at primary PCI centre, median (IQR) hrs 2.2 (1.5, 3.2) 2.5 (1.7, 3.5) 0.354 
Arrival at primary PCI centre to reperfusion, median (IQR) hrs 0.4 (0.3, 0.6) 0.6 (0.4, 0.7) 0.002 
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Initial blood results on admission:    
               Hemoglobin, g/dL 145.6 ± 13.6 145.8 ± 10.3 0.892 
               Platelet count, 103/μL 260.6 ± 60.9 270.9 ± 80.4 0.486 
               Creatinine, μmol/L 80.9 ± 17.7 78.6 ± 18.6 0.546 
               eGFR (ml/min/1.73m2) 90.1 ± 20.4 92.5 ± 28.5 0.679 
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Supplemental Table 5. Procedure characteristics according to availability of MVO data (complete vs. missing). Data 
are mean ± SD, or n (%), unless otherwise stated. 
 MVO data available 
(n=383) 
MVO data missing 
(n=38) 
 P-value  
Culprit artery:    
              Left anterior descending  176 (46%) 15 (40%) 0.497 
              Circumflex 44 (12%) 9 (24%) 0.040 
              Right coronary artery 163 (43%) 14 (37%) 0.606 
>50% stenosis in ³2 major coronary arteries 134 (35%) 10 (26%) 0.370 
Initial TIMI coronary flow grade:  
               £1  










Initial TIMI thrombus grade: 
               3/4 










American Heart Association culprit lesion type A 287 (75%) 30 (79%) 0.695 
Culprit lesion plaque characterisation score ³4 292 (76%) 29 (76%)  0.100 
QCA lesion length pre-drug (mm) 26.8 ± 11.4 25.0 ± 10.0 0.305 
Reperfusion achieved with balloon angioplasty 269 (70%) 32 (84%) 0.089 
Balloon angioplasty pre-stent 354 (92%) 34 (90%) 0.523 
Study drug delivered with thrombectomy catheter 278 (73%) 22 (58%) 0.062 
Total number of stents deployed ³2 115 (30%) 11 (29%) 1.000 
Post-stent dilatation 337 (88%) 29 (76%) 0.072 
Total length of stents deployed from QCA (mm) 34.0 ± 14.4 32.8 ± 14.9 0.638 
QCA reference vessel diameter post-stent (mm) 3.2 ± 0.5 3.2 ± 0.4 0.535 
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Activated clotting time (s) 281.7 ± 88.0 273.0 ± 94.0 0.673 
Intravenous morphine 284 (74%) 27 (71%) 0.700 
Inhaled oxygen (%) 55 (15%) 5 (15%) 1.000 
Glycoprotein IIb/IIIa antagonist (%) 57 (15%) 9 (27%) 0.091 
Duration of study drug infusion (min) 6.5 (2%) 6.4 (2%) 0.679 
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Supplemental Table 6. Analysis of CMR parameters 2–7 days after primary PCI, by subgroups of TIMI flow grade (2 vs. 3) immediately before study drug 
administration (adjusted for MI location [anterior vs. non-anterior]). Treatment effect estimates and interaction with treatment received are shown (see 
footnotes). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated.  
 Treatment group                                      Treatment Effect Interaction 
p-value 
(treatment 




Treatment Effect Interaction 
p-value 
(treatment 















Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg)  
Vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
MVO presence (n/ total) (a)  
     TIMI 2 flow   







2.58 (1.00, 6.65) p=0.051 
0.61 (0.33, 1.14) p=0.119  
1.66 (0.67, 4.13) p=0.257 
0.72 (0.39, 1.34) p=0.298  0.153         
2.06 (0.92, 4.62) p=0.081 
0.66 (0.39, 1.13) p=0.128 0.022 
MVO extent (% of LV mass)† (b)           
     TIMI 2 flow  
     TIMI 3 flow 
3.0 ± 6.2 
2.2 ± 3.4 
2.8 ± 3.9 
2.4 ± 4.8 
5.2 ± 7.2 
2.3 ± 4.3 
0.26 (-0.36, 0.89) p=0.405 
-0.09 (-0.49, 0.31) p=0.661  
0.55 (-0.18, 1.27) p=0.136 
-0.06 (-0.45, 0.34) p=0.777  0.243   
0.43 (-0.17, 1.02) p=0.158 
-0.07 (-0.42, 0.27) p=0.677 0.107 
Myocardial haemorrhage presence (n/ total) (a)  
     TIMI 2 flow  







3.05 (1.12, 8.31) p=0.029 
0.64 (0.34, 1.21) p=0.168 
 
2.14 (0.82, 5.62) p=0.121 
0.66 (0.35, 1.23) p=0.188 
 0.054   
2.55 (1.07, 6.06) p=0.034 
0.65 (0.38, 1.11) p=0.117 
0.009 
Myocardial haemorrhage extent (% LV mass)† (c)  
     TIMI 2 flow  
     TIMI 3 flow 
2.0 ± 5.7 
1.4 ± 2.8 
2.0 ± 2.9 
1.8 ± 3.6 
4.2 ± 6.0 
1.5 ± 3.8 
1.95 (-0.33, 4.24) p=0.093 
0.29 (-1.00, 1.58) p=0.656 
 1.98 (-0.74, 4.69) p=0.151 
0.11 (-1.16, 1.38) p=0.867 
 0.132   0.50 (-0.04, 3.04) p=0.287 
0.20 (-0.91, 1.31) p=0.726 
0.362 
Infarct size (% LV mass) (c)     
     TIMI 2 flow 
     TIMI 3 flow 
28.5 ± 16.4 
26.0 ± 12.6 
30.5 ± 12.7 
24.7 ± 11.7 
31.9 ± 13.5 
22.8 ± 12.3 
2.46 (-3.91, 8.82) p=0.445 
-1.35 (-4.92, 2.22) p=0.460 
 3.00 (-3.48, 9.48) p=0.359 
-2.68 (-6.22, 0.86) p=0.138 
 0.158   2.69 (-2.67, 8.04) p=0.322 
-2.03 (-5.09, 1.03) p=0.195 
0.085 
Myocardial salvage index (c)      
     TIMI 2 flow  
     TIMI 3 flow 
0.4 ± 0.3 
0.4 ± 0.2 
0.3 ± 0.2 
0.4 ± 0.2 
0.3 ± 0.2 
0.4 ± 0.2 
-0.05 (-0.17, 0.08) p=0.464 
0.02 (-0.05, 0.09) p=0.593  
-0.07 (-0.18, 0.04) p=0.205 
0.04 (-0.03, 0.11) p=0.254  0.201   
-0.06 (-0.15, 0.04) p=0.245 
0.03 (-0.03, 0.09) p=0.329 0.117 
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Supplemental Table 7. Analysis of MVO extent (% LV mass) 2-7 days after primary PCI, by subgroups of TIMI flow grade (£2 vs. 
3) immediately before study drug administration, with treatment effects derived by bootstrapping (10,000 replicates, stratified by 
the location of myocardial infarction). 
  Treatment Effect on MVO extent 
 
Treatment Effect on MVO extent 
  Alteplase 10mg vs placebo  Alteplase 20mg vs. placebo  Alteplase (10mg or 20mg) vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value   Estimate (95% CI), p-value 
 












2.80 (-0.09, 5.51) p=0.057 
 
TIMI 3 flow  
  
1.96 (-0.65, 3.20) p=0.237 
  
1.91 (-0.74, 3.01) p=0.287 
   
1.99 (-0.57, 2.92) p=0.246 
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Supplemental Table 8. Analysis of electrocardiographic, biochemical and angiographic parameters, by subgroups of TIMI flow grade (£2 vs. 3) at the time 
of study drug administration (adjusted for MI location [anterior vs. non-anterior]). Treatment effect estimates and interaction with treatment received are 
shown (see footnotes). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. 
 Treatment Group Treatment Effect  Interaction 
p-value 
(treatment 




Treatment Effect Interaction 
p-value 
(treatment 














Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo 
 
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value   
Estimate (95% CI),  
p-value 
Absolute % ST-segment resolution 60 min (a)  
    TIMI flow £2  
    TIMI 3 flow 
45.0 ± 44.3 
50.7± 36.4 
40.6 ± 52.1 
44.4 ± 41.8 
37.7 ± 43.3 
50.5 ± 46.0 
-4.43 (-21.96, 13.1) p=0.621 
-6.89 (-20.50, 6.73) p=0.322 
 
-7.37 (-24.21, 9.47) p=0.392 
-0.34 (-13.59, 12.91) p=0.960 
 0.671   
-6.02 (-20.91, 8.87) p=0.429 
-3.44 (-14.99, 8.11) p=0.560 
0.789 
Troponin T (ng/mL) AUC, 0–24 hours (b)       
   TIMI flow £2  
    TIMI 3 flow 
2.66 [1.10, 5.20] 
3.16 [1.16, 5.76] 
2.94 [1.73, 6.86] 
2.67 [1.53, 5.71] 
4.60 [1.20, 8.19] 
3.47 [1.57, 6.30] 
1.67 (0.96, 2.89) p=0.071 
1.38 (0.92, 2.08) p=0.120 
 
1.83 (1.07, 3.12) p=0.029 
1.34 (0.90, 2.00) p=0.151 
 0.662   
1.75 (1.09, 2.80) p=0.021 
1.36 (0.96, 1.92) p=0.082 
0.402 
TIMI coronary flow grade post-PCI £2 (c)  
  TIMI flow £2  







0.72 (0.31, 1.66) p=0.432  
2.80 (0.95, 8.34) p=0.064  
 
1.09 (0.50, 2.39) p=0.838  
2.53 (0.84, 7.61) p=0.099 
 0.134   
0.90 (0.45, 1.81) p=0.762  
2.66 (0.98, 7.27) p=0.056 
0.071 
 
Corrected TIMI frame count post-PCI (b) 
 
  TIMI flow £2  
  TIMI 3 flow 
26.5 [17.4, 39.4] 
17.7 [12.0, 24.0] 
22.4 [15.5, 35.9] 
20.0 [14.0, 26.0] 
28.0 [21.8, 40.5] 
17.4 [12.9, 24.0] 
0.91 (0.73, 1.13) p=0.372 
1.18 (1.00, 1.39) p=0.049 
 
1.07 (0.87, 1.32) p=0.534 
1.08 (0.92, 1.26) p=0.377 
 0.095   
0.99 (0.82, 1.19) p=0.902 
1.12 (0.98, 1.29) p=0.099 
0.276 
Myocardial perfusion grade post-PCI £1 (c)   
  TIMI flow £2  







0.95 (0.42, 2.13) p=0.895 
1.43 (0.77, 2.65) p=0.264 
 
1.65 (0.75, 3.66) p=0.214 
0.71 (0.37, 1.37) p=0.308 
 0.050   
1.27 (0.63, 2.54) p=0.501  
1.02 (0.59, 1.77) p=0.932  
0.634 
 
(a) Treatment effect estimates reported as mean differences between groups. 
(b) Data analysed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups. 
(c) Treatment effect estimates reported as odds ratios between groups, from a logistic regression model. 
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The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive. 
*Missing data: % ST-segment resolution (n=43); Troponin AUC (n=115); corrected TIMI frame count post-PCI (n=2). 
Abbreviations: AUC, area-under-the-curve; CI, confidence interval; IQR, interquartile range; MI, myocardial infarction; SD, standard deviation; 
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Supplemental Table 9. Analysis of coagulation variables, at 2 hours, at 24 hours, and at 24 hours compared to baseline, by subgroups of TIMI flow 
grade (£2 vs. 3) immediately before study drug administration (adjusted for MI location [anterior vs. non-anterior]). Treatment effect estimates and 
interaction with treatment received are shown (see footnotes). Data are median [IQR], unless otherwise stated.  
 Treatment Group                    Treatment Effect Interaction 
p-value 
(treatment 




Treatment Effect Interaction 
p-value 
(treatment 














Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg) vs. 
placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
Fibrinogen (g/L) 2 hours post-PCI (a)  
  TIMI flow £2  
  TIMI 3 flow 
3.3 [2.7, 4.0] 
3.3 [2.8, 3.9] 
3.2 [2.6, 3.6] 
3.0 [2.6, 3.8] 
3.1 [2.7, 3.6] 
3.3 [2.8, 3.7] 
0.98 (0.88, 1.1) p=0.784 
0.96 (0.88, 1.04) p=0.279 
 
0.94 (0.84, 1.05) p=0.250 
0.97 (0.89, 1.05) p=0.441 
 0.684   
0.96 (0.87, 1.05) p=0.391 
0.96 (0.90, 1.03) p=0.282 
0.955 
Plasminogen (U/dL) 2 hours post-PCI (b)     
  TIMI flow £2  
  TIMI 3 flow 
95.0 [88.3, 101.0] 
96.0 [87.0, 104.5] 
91.0 [81.5, 100.8] 
88.0 [80.0, 98.0] 
83.5 [74.8, 92.0] 
84.0 [77.0, 92.0] 
-2.66 (-8.56, 3.25) p=0.378 
-6.90 (-11.20, -2.66) p=0.002 
 -10.88 (-16.52, -5.25) p<0.001 
10.49 (-14.73, -6.25) p<0.001 
 0.378   -7.16 (-12.23, -2.09) p=0.006 
-8.74 (-12.45, -5.03) p<0.001 
0.623 
Fibrin D-dimer (ng/mL) 2 hours post-PCI (a)     
  TIMI flow £2  
  TIMI 3 flow 
101.0 [69.5, 138.3] 
117.0 [74.8, 169.0] 
319.5 [215.5, 633.0] 
354.0 [224.0, 593.0] 
513.5 [266.8, 831.5] 
421.0 [275.5, 641.5] 
3.64 (2.53, 5.22) p<0.001 
3.15 (2.43, 4.09) p<0.001  
4.91 (3.48, 6.93) p<0.001 
3.88 (3.00, 5.03) p<0.001  0.563   
4.29 (3.15, 5.83) p<0.001 
3.50 (2.80, 4.39) p<0.001 0.299 
Prothrombin fragment F1+2 (pmol/L) 2 hours post-PCI (a)      
  TIMI flow £2  
  TIMI 3 flow 
165.0 [134.0, 220.8] 
155.5 [124.1, 267.0] 
161.1 [124.9, 260.8] 
200.3 [144.0, 328.2] 
201.5 [147.4, 303.0] 
199.1 [153.2, 303.0] 
1.20 (0.92, 1.57) p=0.183 
1.26 (1.04, 1.53) p=0.019  
1.22 (0.94, 1.57) p=0.136 
1.19 (0.98, 1.44) p=0.078  0.909   
1.21 (0.96, 1.52) p=0.103 
1.23 (1.04, 1.45) p=0.017 0.925 
Tissue plasminogen activator (ng/mL) 2 hours post-PCI (a)     
  TIMI flow £2  
  TIMI 3 flow 
11.0 [8.3, 13.0] 
11.0 [9.0, 13.0] 
14.0 [11.0, 16.0] 
13.0 [11.0, 17.0] 
15.0 [12.0, 19.3] 
14.0 [12.0, 16.5] 
1.26 (1.00, 1.59) p=0.056 
1.30 (1.10, 1.54) p=0.003  
1.45 (1.16, 1.82) p=0.001 
1.48 (1.25, 1.76) p<0.001  0.977   
1.36 (1.11, 1.66) p=0.003 
1.39 (1.20, 1.61) p<0.001 0.869 
Fibrinogen (g/L) 24 hours post-PCI (a)          
  TIMI flow £2 
  TIMI 3 flow 
3.6 [3.0, 4.5] 
3.8 [3.3, 4.6] 
3.6 [3.1, 4.4] 
3.5 [2.8, 4.3] 
3.6 [3.0, 4.4] 
3.5 [3.0, 4.1] 
1.03 (0.92, 1.16) p=0.576 
0.94 (0.86, 1.02) p=0.143  
0.99 (0.89, 1.11) p=0.927 
0.92 (0.85, 1.00) p=0.063  0.384   
1.01 (0.92, 1.12) p=0.791 
0.93 (0.87, 1.00) p=0.052 0.176 
Plasminogen (U/dL) 24 hours post-PCI (b)          
  TIMI flow £2 
  TIMI 3 flow 
91.0 [86.0, 102.0] 
96.0 [83.0, 107.0] 
91.6 [84.8, 99.3] 
88.0 [77.0, 99.3] 
86.0 [77.0, 94.0] 
90.0 [80.0, 96.0] 
0.14 (0.00, 45.15) p=0.506 
0.00 (0.00, 0.07) p=0.002  
0.00 (0.00, 0.34) p=0.021 
0.00 (0.00, 0.16) p=0.005  0.230   
0.01 (0.00, 1.85) p=0.086 
0.00 (0.00, 0.06) p<0.001 0.519 
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Fibrin D-dimer (ng/mL) 24 hours post-PCI (a)          
  TIMI flow £2 
  TIMI 3 flow 
103.0 [59.0, 150.0] 
130.0 [80.5, 201.5] 
162.0 [112.0, 371.8] 
190.0 [112.8, 379.0] 
224.0 [151.0, 344.0] 
224.0 [133.0, 325.0] 
2.05 (1.46, 2.87) p<0.001 
1.44 (1.13, 1.85) p=0.004  
2.11 (1.51, 2.94) p<0.001 
1.56 (1.23, 1.99) p<0.001  0.205   
2.08 (1.55, 2.78) p<0.001 
1.50 (1.22, 1.85) p<0.001 0.078 
Prothrombin fragment F1+2 (pmol/L) 24 hours post-PCI (a)          
  TIMI flow £2 
  TIMI 3 flow 
197.0 [145.0, 262.2] 
226.0 [153.6, 334.0] 
191.7 [129.7, 297.3] 
226.8 [173.5, 324.6] 
204.0 [155.0, 321.0] 
234.0 [166.4, 327.7] 
1.04 (0.80, 1.36) p=0.750 
1.09 (0.89, 1.32) p=0.404 
 1.21 (0.93, 1.58) p=0.159 
1.08 (0.89, 1.31) p=0.416 
 0.643   1.13 (0.89, 1.42) p=0.319 
1.08 (0.92, 1.28) p=0.336 
0.802 
Tissue plasminogen activator (ng/mL) 24 hours post-PCI (a)          
  TIMI flow £2 
  TIMI 3 flow 
10.0 [8.0, 12.0] 
9.0 [7.0, 11.5] 
11.0 [8.8 12.0] 
10.0 [8.0 12.0] 
10.0 [8.0, 13.0] 
10.0 [8.0, 12.0] 
1.02 (0.84, 1.24) p=0.829 
1.04 (0.91, 1.20) p=0.549 
 1.05 (0.87, 1.28) p=0.594 
1.14 (0.99, 1.31) p=0.068 
 0.803   1.04 (0.88, 1.23) p=0.666 
1.09 (0.97, 1.23) p=0.152 
0.627 
Ratio of fibrinogen at 24 hours relative to baseline (a)          
  TIMI flow £2 
  TIMI 3 flow 
1.12 [1.00, 1.26] 
1.20 [1.00, 1.33] 
1.17 [1.10, 1.35] 
1.10 [0.90, 1.35] 
1.16 [1.00, 1.37] 
1.11 [1.00, 1.25] 
1.08 (0.99, 1.17) p=0.077 
0.95 (0.89, 1.01) p=0.101  
1.05 (0.96, 1.14) p=0.296 
0.95 (0.89, 1.00) p=0.071  0.040   
1.06 (0.99, 1.14) p=0.107 
0.95 (0.90, 1.00) p=0.044 0.013 
Change in plasminogen (U/dL) at 24 hours relative to baseline (b)          
  TIMI flow £2 
  TIMI 3 flow 
1.0 [-4.0, 5.5] 
2.0 [-3.0, 6.0] 
-3.0 [-9.0, 4.0] 
-6.5 [-10.3, 0.0] 
-6.0 [-11.5, -2.3] 
-7.0 [-11.8, -0.3] 
-2.57 (-6.46, 1.32) p=0.197 
-7.52 (-10.36, -4.67) p<0.001  
-7.05 (-10.89, -3.21) p<0.001 
-7.22 (-10.04, -4.40) p<0.001  0.074   
-4.87 (-8.25, -1.49) p=0.005 
-7.37 (-9.81, -4.93) p<0.001 0.239 
Ratio of fibrin D-dimer at 24 hours relative to baseline (a)          
  TIMI flow £2 
  TIMI 3 flow 
1.1 [0.8, 1.3] 
1.3 [0.9, 1.7] 
1.8 [1.2, 3.3] 
1.7 [1.0, 2.5] 
1.6 [1.0, 2.7] 
2.2 [1.4, 3.4] 
2.01 (1.46, 2.77) p<0.001 
1.26 (1.00, 1.59) p=0.055  
1.67 (1.22, 2.30) p=0.002 
1.76 (1.40, 2.22) p<0.001  0.019   
1.83 (1.38, 2.42) p<0.001 
1.49 (1.22, 1.83) p<0.001 0.249 
Ratio of prothrombin fragment F1+2 at 24 hours relative to baseline (a)          
  TIMI flow £2 
  TIMI 3 flow 
1.2 [1.0, 1.6] 
1.4 [0.9, 1.9] 
1.5 [13.9, 2.0] 
1.4 [1.0, 1.6] 
1.3 [1.0, 1.9] 
1.4 [1.2, 2.1] 
1.26 0.93, 1.71) p=0.134 
0.87 (0.70, 1.09) p=0.219 
 
1.23 (0.91, 1.66) p=0.173 
1.16 (0.93, 1.45) p=0.182 
 0.520   
1.25 (0.96, 1.62) p=0.103 
1.01 (0.83, 1.22) p=0.937 
0.200 
Ratio of tissue plasminogen activator at 24 hours relative to baseline (a)          
  TIMI flow £2 
  TIMI 3 flow 
1.1 [0.9, 1.3] 
0.9 [0.8, 1.2] 
1.2 [1.0, 1.3] 
1.0 [0.8, 1.2] 
1.1 [0.9, 1.3] 
1.1 [0.8, 1.4] 
1.05 (0.78, 1.41) p=0.761 
0.84 (0.68, 1.05) p=0.121  
0.98 (0.73, 1.32) p=0.894 
0.95 (0.76, 1.18) p=0.635  0.454   
1.01 (0.78, 1.31) p=0.926 
0.89 (0.74, 1.08) p=0.240 0.444 
 
(a) Data analysed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups. 
(b) Treatment effect estimates reported as mean differences between groups. 
The p values and 95% CI have not been adjusted for multiplicity, therefore these analyses should be interpreted as exploratory and not definitive. 
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*Missing data: coagulation parameters 2 hours post-PCI (n=75); coagulation parameters 24 hours post-PCI (n=71); change in coagulation 
parameters at 24 hours relative to baseline (n=97). 
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Reported on page 
No
Title and abstract
1a Identification as a randomised trial in the title Randomised trial is 
not stated in title, 
because the 
submitted manuscript 
is a substudy of a 
randomised trial.
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for 
abstracts)
Page 4 main 
manuscript
Introduction




2b Specific objectives or hypotheses Pages 8 & 9 main 
manuscript
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio Page 10 to 12 main 
manuscript, and page 
15 supplement.
Trial design
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons Page 14 supplement
4a Eligibility criteria for participants Pages 3 – 5 
supplement
Participants
4b Settings and locations where the data were collected Page 10 main 
manuscript
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they 
were actually administered
Page 11 main 
manuscript
6a Completely defined pre-specified primary and secondary outcome measures, including how and when 
they were assessed
Page 9 main 
manuscript
Outcomes
6b Any changes to trial outcomes after the trial commenced, with reasons Page 10 main 
manuscript
7a How sample size was determined Page 10 main 
manuscript
Sample size
7b When applicable, explanation of any interim analyses and stopping guidelines Page 14 supplement
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Randomisation:









9 Mechanism used to implement the random allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal the sequence until interventions were assigned
Pages 10 and 11 
main manuscript
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned 
participants to interventions
Pages 10 and 11 
main manuscript
11a If done, who was blinded after assignment to interventions (for example, participants, care providers, 
those assessing outcomes) and how
Pages 10 and 11 
main manuscript
Blinding
11b If relevant, description of the similarity of interventions n/a
12a Statistical methods used to compare groups for primary and secondary outcomes Pages 13 and 14 
main manuscript
Statistical methods
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses Pages 13 and 14 
main manuscript
Results
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, 
and were analysed for the primary outcome
Page 37 main 
manuscript
Participant flow (a 
diagram is strongly 
recommended) 13b For each group, losses and exclusions after randomisation, together with reasons Page 37 main 
manuscript
14a Dates defining the periods of recruitment and follow-up Page 10 main 
manuscript
Recruitment
14b Why the trial ended or was stopped Page 14 supplement
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Pages 27 to 28 main 
manuscript
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis 
was by original assigned groups
Pages 32 to 36 main 
manuscript
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval)
Pages 32 to 36 main 
manuscript and pages 
16 to 26 supplement
Outcomes and 
estimation
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Pages 32 to 36 main 
manuscript and pages 
16 to 26 supplement
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory
Pages 32 to 36 main 
manuscript and pages 
16 to 26 supplement
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) These were detailed 
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in the original 
publication of the T-
TIME randomised 
trial. McCartney P et 






submitted to Heart 
is a substudy of the 
T-TIME trial.
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Page 21 main 
manuscript
Generalisability 21 Generalisability (external validity, applicability) of the trial findings Page 21 main 
manuscript
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant 
evidence
Pages 19 to 21 main 
manuscript
Other information
Registration 23 Registration number and name of trial registry Page 8 main 
manuscript
Protocol 24 Where the full trial protocol can be accessed, if available Page 10 main 
manuscript
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Page 2
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
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